Cosmos Health (COSM) POS AM 9 May 18 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017
Document And Entity Information
Entity Registrant Name	Cosmos Holdings Inc.
Entity Central Index Key	1,474,167
Document Type	S1
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,017

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 782,853	$ 716,590
Accounts receivable	1,255,596	661,850
Accounts receivable - related party	171,392
Inventory	3,093,521	464,219
Other receivable		131,900
Prepaid expenses and other current assets	1,482,192	646,530
Prepaid expenses and other current assets - related party	2,724,972	15,523
TOTAL CURRENT ASSETS	9,510,526	2,636,612
Other assets	1,008,579	429,203
Property and equipment, net	114,567	52,715
Intangible assets, net	41,994
TOTAL ASSETS	10,675,666	3,118,530
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,778,333	577,932
Accounts payable and accrued expenses - related party	387,847	13,759
Convertible notes payable, net of unamortized discount of $2,989,110 and $0, respectively	121,604
Notes payable, net of unamortized discount of $126,763 and $110,561, respectively	9,951,745	2,872,472
Notes payable - related party	97,979	160,391
Loans payable		17,938
Loans payable - related party	7,213	148,250
Taxes payable	1,358,789	1,080,590
TOTAL CURRENT LIABILITIES	13,703,510	4,871,332
TOTAL LIABILITIES	13,703,510	4,871,332
Commitments and Contingencies (see Note 9)
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively
Common stock, $0.001 par value; 300,000,000 shares authorized; 12,825,393 and 12,587,053 shares issued and 12,666,704 and 12,587,053 outstanding as of December 31, 2017 and December 31, 2016, respectively	12,825	12,587
Additional paid-in capital	5,652,429	287,293
Accumulated other comprehensive loss	(1,385,229)	(1,050,463)
Accumulated deficit	(7,211,987)	(1,002,219)
Treasury Stock	(95,882)
TOTAL STOCKHOLDERS' DEFICIT	(3,027,844)	(1,752,802)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 10,675,666	$ 3,118,530

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT LIABILITIES:
Convertible notes payeble, net of unamortized discount	$ 2,989,110	$ 0
Notes payable, net of unamortized discount	$ 126,763	$ 110,561
SHAREHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	12,825,393	12,587,053
Common stock, shares, outstanding	12,666,704	12,587,053

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
REVENUE
Revenue	$ 30,013,378	$ 6,755,436
COST OF REVENUE	28,057,111	6,154,396
GROSS PROFIT	1,956,267	601,040
OPERATING EXPENSES
General and administrative expenses	4,852,801	794,099
Depreciation and amortization expense	25,903	9,448
Impairment of goodwill	1,949,884
TOTAL OPERATING EXPENSES	6,828,588	803,547
LOSS FROM OPERATIONS	(4,872,321)	(202,507)
OTHER INCOME (EXPENSE)
Other income		19
Interest expense - related party	(2,592)	(264)
Interest expense	(748,474)	(189,687)
Non-cash interest expense	(886,483)	(16,063)
Other expense	(27,492)	(12,764)
Foreign currency transaction gain (loss)	330,395	(178,967)
TOTAL OTHER EXPENSE	(1,334,646)	(397,726)
LOSS BEFORE INCOME TAXES	(6,206,967)	(600,233)
INCOME TAX EXPENSE	(2,801)	(769)
NET LOSS	(6,209,768)	(601,002)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation gain (loss)	(334,766)	55,215
TOTAL OTHER COMPREHENSIVE LOSS	$ (6,544,534)	$ (545,787)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.49)	$ (0.05)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic and Diluted	12,780,013	12,564,824

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Treasury Stock	Accumulated Other Comprehensive Loss	Total
Beginning Balance, Shares at Dec. 31, 2015		12,563,053
Beginning Balance, Amount at Dec. 31, 2015		$ 12,563	$ 246,541	$ (401,217)		$ (1,105,678)	$ (1,247,791)
Foreign currency translation effect						55,215	55,215
Issuance of common stock for the exercise of options, Shares		24,000
Issuance of common stock for the exercise of options, Amount		$ 24	23,976				24,000
Stock option expense			16,636				16,636
Contribution of capital by an officer			140				140
Fair value of warrants issued for services
Net income				(601,002)			(601,002)
Ending Balance, Shares at Dec. 31, 2016		12,587,053
Ending Balance, Amount at Dec. 31, 2016		$ 12,587	287,293	(1,002,219)		(1,050,463)	(1,752,802)
Foreign currency translation effect						(334,766)	(334,766)
Stock option expense			338,792				338,792
Sale of common stock and warrants, Shares		14,340
Sale of common stock and warrants, Amount		$ 14	91,766				91,780
Acquisition of subsidiary, Shares		170,000
Acquisition of subsidiary, Amount		$ 170	1,478,830				1,479,000
Issuance of stock for services, Shares		54,000
Issuance of stock for services, Amount		$ 54	401,746				401,800
Relative fair value of warrants issued with convertible debt			1,545,288				1,545,288
Beneficial conversion feature discount related to convertible notes payable			1,140,711				1,140,711
Fair value of warrants issued for services			368,003				368,003
Purchase of treasury stock, Shares					(138,689)
Purchase of treasury stock, Amount					$ (1,387)		(1,387)
Purchase of treasury stock from officer					(94,495)		(94,495)
Net income				(6,209,768)			(6,209,768)
Ending Balance, Shares at Dec. 31, 2017		12,825,393			(138,689)
Ending Balance, Amount at Dec. 31, 2017		$ 12,825	$ 5,652,429	$ (7,211,987)	$ (95,882)	$ (1,385,229)	$ (3,027,844)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,209,768)	$ (601,002)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense	25,903	9,448
Amortization of debt discounts	518,481	16,063
Stock-based compensation	338,792	16,636
Issuance of common stock for services	401,800
Fair value of warrants issued for services	368,003
Loss on goodwill impairment	1,949,884
Changes in Assets and Liabilities:
Accounts receivable	(534,909)	(565,306)
Accounts receivable - related party	(171,392)
Inventory	(2,623,788)	(272,345)
Prepaid expenses	(669,713)	(585,821)
Prepaid expenses - related party	(2,709,449)	(15,523)
Other assets	(531,324)	(369,287)
Accounts payable and accrued expenses	496,450	381,512
Accounts payable and accrued expenses - related party	312,666	(126,754)
Taxes payable	278,223	48,508
Deferred revenue		(62,210)
NET CASH USED IN OPERATING ACTIVITIES	(8,760,141)	(2,126,081)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(55,337)	(12,816)
Payment of financing arrangement fee		(131,900)
Cash received from acquisition	40,858
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(14,479)	(144,716)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable	(239,286)
Proceeds from convertible note payable	2,686,000
Payment of related party note payable	(84,755)	(63,312)
Payment of note payable	(487,476)	(176,218)
Proceeds from note payable	7,541,413	2,871,993
Payment of related party loan	(978,730)	(15,300)
Proceeds from related party loan	817,040	148,250
Payment of loans payable	(20,437)	(45,374)
Sale of common stock and warrants	91,780
Proceeds from the exercise of stock options		24,000
Purchase of treasury stock	(34,460)
Capital contribution		140
NET CASH PROVIDED BY FINANCING ACTIVITIES	9,291,089	2,744,179
Effect of exchange rate changes on cash	(450,206)	45,159
NET INCREASE IN CASH	66,263	518,541
CASH AT BEGINNING OF YEAR	716,590	198,049
CASH AT END OF YEAR	782,853	716,590
Supplemental Disclosure of Cash Flow Information
Cash paid during the period: Interest	130,531	30,396
Cash paid during the period: Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Acquisition of Decahedron	1,479,000
Reversal of proceeds due from noteholder due to repayment of note	24,044
Discounts related to warrants issued with convertible debentures	1,545,288
Discounts related to beneficial conversion features of convertible debentures	1,140,711
Related party accrual for repurchase of shares of common stock	$ 61,422

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS	Cosmos Holdings, Inc. (“Cosmos”, “The Company”, “we”, or “us”) was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009 for the purpose of acquiring and operating commercial real estate and real estate related assets. On September 27, 2013 (the “Closing”), Cosmos Holdings Inc. a Nevada corporation (“Cosmos Holdings, Inc.” or the “Registrant”), closed a reverse take-over transaction by which it acquired a private company whose principal activities are the trading of products, providing representation, and provision of consulting services to various sectors. Pursuant to a Share Exchange Agreement (the “Exchange Agreement”) between the Registrant and Amplerissimo Ltd, a company incorporated in Cyprus (“Amplerissimo”), the Registrant acquired 100% of Amplerissimo’s issued and outstanding common stock. On August 1, 2014, we, through our Cypriot subsidiary Amplerissimo, formed SkyPharm S.A. a Greek corporation (“SkyPharm”) whose principal activities and operations are the development, marketing and sales of pharmaceutical, wellness and cosmetic products. On February 10, 2017, the Company and Decahedron Ltd, a UK Corporation (“Decahedron”) consummated the transactions contemplated by the Stock Purchase Agreement, dated November 17, 2016 as amended (the “Decahedron SPA”). Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company (the “Stock Consideration”), which were delivered following the closing in exchange for all of the Ordinary Shares of Decahedron for the Stock Consideration. In accordance with the terms of the SPA, Mr. Lazarou remained as a director and officer of Decahedron. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. We are currently focusing our existing operations on expanding the business of SkyPharm and our new subsidiary Decahedron, we have concentrated our efforts on becoming an international pharmaceutical company. The Company’s focus will be on Branded Pharmaceuticals, Over-the-Counter (OTC) medicines, and Generic Pharmaceuticals. The Company also intends to expand into Cosmetic-Beauty Products as well as Food Supplements and we target areas where we can build and maintain a strong position. The Company uses a differentiated operating model based on a lean, nimble and decentralized structure, an emphasis on low risk license acquisition as well as Research & Development and our ability to be better owners of pharmaceutical assets than others. This operating model and the execution of our corporate strategy are enabling the Company to achieve sustainable growth and create shareholder value. We regularly evaluate and, where appropriate, execute on opportunities to expand through the acquisition of branded pharmaceutical products and pharmaceutical companies in areas that will serve patients that we believe will offer above average growth characteristics and attractive margins. In particular, we look to continue to enhance our pharmaceutical and over the counter product lines by acquiring or licensing rights to additional products and regularly evaluate selective acquisition opportunities. The Company had $30,013,378 in total revenues and expended $28,057,111 for the year ended December 31, 2017, in connection with these operations. Going Concern The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company generated a net loss of $6,209,768 for the year ended December 31, 2017, and has a working capital deficit of $4,192,984 and an accumulated deficit of $7,211,987 as of December 31, 2017. These conditions raise substantial doubt of the Company’s ability to continue as a going concern. The Company has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd, SkyPharm S.A. and Decahedron Ltd. All significant intercompany balances and transactions have been eliminated. Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2017 and December 31, 2016, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. For the year ended December 31, 2017, the amounts in these accounts were $65,613, $398,841 (the Euro equivalent of which was €331,759) and $27,542 (the British Pound equivalent of which was £20,358). At December 31, 2016, the amounts in these accounts were $3,143 and $19,876 (the Euro equivalent of which was €18,836). Additionally, for the years ended December 31, 2017 and 2016, the Company had cash on hand in the amount of $290,857 and $693,570, respectively. Accounts Receivable Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Tax Receivables The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiary in Greece, SkyPharm S.A., does not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of December 31, 2017 and 2016, the Company had a VAT net receivable balance of $961,220 and $398,126, respectively, recorded on the balance sheet as other assets. Inventory Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years Depreciation expense was $17,370 and $9,448 for the years ended December 31, 2017 and December 31, 2016, respectively. Intangible Assets Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At December 31, 2017, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $8,533 and $0 for the years ended December 31, 2017 and 2016, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Goodwill and Intangibles The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no record goodwill value. As a result of the acquisition of Decahedron, the Company tested and impaired 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the year ended December 31, 2017. Fair Value Measurement The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2017. Cash is considered to be highly liquid and easily tradable as of December 31, 2017 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Revenue Recognition We recognize revenue net of the VAT receivable. We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided. Stock-based Compensation The Company records stock based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees". Foreign Currency Translations and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2017 2016 Number of 10% clients 3 2 Percentage of total revenue 49.63 % 52.49 % Percentage of total AR 20.68 % 26.09 % Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus, Greece and the United Kingdom of England. The corporate income tax rate in Cyprus is 12.5% and 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in the United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2017 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management's judgment, the position is not more-likely-then-not sustainable upon audit based on the position's technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of December 31, 2017 the Company had no uncertain tax positions recorded in any jurisdiction where it is subject to income tax. Basic and Diluted Net Income (Loss) per Common Share Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in years with net income. Basic and diluted loss per share for each of the years ended December 31, 2016 and 2017 is the same due to the anti-dilutive nature of potential common stock equivalents. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-11,“ Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). Part I relates to the accounting or certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down Round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified as equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted and may be applied on a retrospective basis, including in an interim period. The Company early adopted ASU 2017-11 during the year ended December 31, 2017. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The Company does not believe that the adoption of ASU No. 2017-4 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition of assets or a business. ASU No. 2017-01 is effective for the Company’s fiscal year commencing on January 1, 2018. The effect of this guidance is to be applied prospectively and early adoption is permitted. The Company does not believe that the adoption of ASU No. 2017-01 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require lessees to recognize assets and liabilities for the rights and obligations created by most leases on the balance sheet. The changes become effective for the Company’s fiscal year beginning January 1, 2020. Modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, is required with an option to use certain transition relief. The Company expects this ASU will increase its current assets and current liabilities, but have no net material impact on its consolidated financial statements. In July 2015, the Financial Accounting Standards Board issued Simplifying the Measurement of Inventory, Topic 330 (ASU No 2015-11). ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to lower of cost or net realizable value. The new standard is effective for the Company for fiscal years and interim periods beginning after December 15, 2016. The Company adopted this standard in the first quarter of fiscal 2017, applying it prospectively. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements. In May 2014, the FASB issued ASU 2014-09-Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. As of January 1, 2018, the Company has adopted the modified retrospective approach in accordance with ASC 606 – Revenue from Contracts with Customers and recognizes revenue at the point in time at which the customer obtains control of the entity and the Company has satisfied its performance obligations. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

ACQUISITION OF DECAHEDRON, LTD.

ACQUISITION OF DECAHEDRON, LTD.	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 2 - ACQUISITION OF DECAHEDRON, LTD.	On February 10, 2017, the Company completed the acquisition pursuant to the Decahedron SPA acquiring 100% of the outstanding shares of Decahedron, a United Kingdom company. Decahedron is a pharmaceuticals wholesaler which specializes in imports and exports of branded and generic pharmaceutical products within the EEA and around the world. At closing, the Company acquired 100% of Decahedron’s outstanding shares and in exchange for 170,000 shares of Cosmos common stock valued at $1,479,000 (the “Acquisition”). The Company recognized cash of $40,858 acquired on acquisition. The Company recognized the remaining Decahedron assets acquired and liabilities assumed based upon the fair value of such assets and liabilities measured as of the date of acquisition. The aggregate purchase price for Decahedron has been allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the license held by Decahedron for the wholesale of pharmaceuticals in the United Kingdom and Europe, the remainder has been allocated to goodwill, none of which is tax deductible. During the year ended December 31, 2017, we recorded an adjustment of $28,002 primarily related to other assets and an adjustment of the accounts payable associated with the Decahedron acquisition. We finalized our allocation of the purchase price during the year ended December 31, 2017. The final allocation of the purchase price as of December 31, 2017, is as follows: Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884 The components of the acquired intangible assets were as follows (in thousands): Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 - _____________ (a) U.K Pharmaceutical Wholesale Distribution License Unaudited Supplemental Pro Forma Data The unaudited pro forma statements of operations data for the year ended December 31, 2017 and 2016, below, give effect to the Decahedron Acquisition, described above, as if it had occurred at January 1, 2016. These amounts have been calculated after applying our accounting policies and adjusting the results of Decahedron intangible amortization that would have been charged assuming the fair value adjustments had been applied and incurred since January 1, 2016. This pro forma data is presented for informational purposes only and does not purport to be indicative of our future results of operations. Revenue of $4,221,751 and net loss of $441,553 since the acquisition date are included in the consolidated statement of operations and comprehensive income (loss) for year ended December 31, 2017. Unaudited proforma results of operations for the year ended December 31, 2017 and 2016 as though the Company acquired Decahedron on the first of each fiscal year are set forth below. Years Ended December 31, 2017 2016 Revenues $ 30,206,825 $ 8,756,772 Cost of revenues 28,256,544 8,128,159 Gross profit 1,950,281 628,613 Operating expenses 6,856,585 991,901 Operating loss (4,906,304 ) (363,288 ) Other income (expense) (1,372,288 ) (506,343 ) Income tax (expense) (2,801 ) 30,803 Net Loss $ (6,281,393 ) $ (838,828 ) Other comprehensive loss (343,766 ) 1,940 Comprehensive net loss $ (6,616,159 ) $ (836,888 ) The purchase price exceeded the estimated fair value of the net assets acquired by $1,949,884 which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from Decahedron and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. At the conclusion of the acquisition, goodwill was reviewed for impairment and it was determined that indicators of impairment existed. As of December 31, 2017, after our assessment of the totality of the events that could impair goodwill, it was the Company’s conclusion “it is more likely than not” that the Goodwill was impaired. As a result of the Company’s assessment, 100% of the goodwill of $1,949,884 was recorded as an impairment of goodwill.

PREPAID FINANCING COSTS

PREPAID FINANCING COSTS	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 3 - PREPAID DEFERRED FINANCING COSTS	On February 28, 2016, the Company entered into an agreement with Synthesis Management Limited (“Synthesis Management”) for the purpose of securing additional financing for the Company. On September 28, 2016, the Company advanced €125,000 ($133,725) to Synthesis Management, as part of the aforementioned agreement. From August 8, 2016, through December 31, 2017, the Company paid a total of €946,426 ($1,137,793) to Mr. Spyros Papadopoulos and to two funds controlled by Mr. Spyros Papadopoulos. More specifically, the Company paid directly to Mr. Spyros Papadopoulos a total of €587,293 ($706,044), to Synthesis Management a total of €178,293 ($214,344), and to Synthesis Multi-Asset Architecture SICAV-SIF a total of €180,840 ($217,406) for advisory fees for the Company’s financing. As of April 18, 2018, an advisory consulting agreement was entered into. See Note 12, Subsequent Events. During the year ended December 31, 2017, the Company fully expensed the costs and the balance of the prepaid financing costs as of December 31, 2017, is $0.

CAPITAL STRUCTURE

CAPITAL STRUCTURE	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 4 - CAPITAL STRUCTURE	Reverse Stock Split On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, which have liquidation preference over the common stock and are non-voting. As of December 31, 2017 and December 31, 2016, no preferred shares have been issued. Common Stock The Company is authorized to issue 300 million shares of common stock and had issued 10,000,000 in connection with the merger and had 2,558,553 shares issued prior to the merger with Amplerissimo. On September 27, 2013, the Company completed the acquisition of Amplerissimo through the issuance of 10,000,000 shares of Common Stock to Dimitrios Goulielmos, the sole shareholder of Amplerissimo, the Company had 12,558,553 shares of Common Stock issued and outstanding. On February 10, 2017 the Company and Decahedron consummated the acquisition of Decahedron SPA. Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company, which were delivered at closing in exchange for all of the Ordinary Shares of Decahedron for the Stock Consideration. Purchase of Treasury Shares Effective October 2, 2017, the Company entered into to a stock purchase agreement dated September 30, 2017, whereby for consideration of $1,387 the Company purchased 138,689 shares of its common stock from a third party investor. The shares were transferred to the Company on October 17, 2017 and will be held in treasury. On December 19, 2017, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €80,000 ($94,495) the Company will purchase 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares will occur on December 19, 2017, the date of signing, however the Company is entitled to pay the full consideration in tranches until July 2018. As of December 31, 2017, the Company has paid consideration of €28,000 ($33,073) and has an amount due to related party of €52,000 ($61,422). The shares were returned to the Company in February 2018. As of the date of this filing, the Company has paid an additional consideration of €32,000 ($38,470) and has an amount due to related party of €20,000 ($24,044). Exercise of Options On November 4, 2016, the Board of Directors authorized the exercise of stock options held by a former director to purchase 240,000 shares of common stock and the Company recorded $24,000 in proceeds. Shares Issued for Services On March 1, 2017, the Company entered into a four-month consulting agreement with a third party investment advisory firm for consideration of 500 restricted shares of common stock to be issued during the period of the agreement for any introductions and related contributions the Company receives as a result of those introductions. As of December 31, 2017, no consideration has been earned and no shares have been issued related to this agreement. On May 1, 2017, the Company entered into an 8-month consulting agreement with a third party for web design services commencing on May 1, 2017 and terminating on January 1, 2018. As compensation for creating, delivering and maintaining a website, the Company issued 2,000 shares of common stock on May 24, 2017. The shares were valued at $14,400, which was fully recognized in the year ended December 31, 2017. On May 1, 2017, the Company entered into a five-month consulting agreement with a third party advisory firm for consideration of 2,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.20 per share or $14,400, which was fully recognized in the year ended December 31, 2017. On May 8, 2017, the Company entered into a one-year consulting agreement for advisory services with a third party investment relations firm. On May 18, 2017, the Company issued to the consultant 30,000 shares of the Company’s common stock valued at $219,000, which was fully recognized in the year ended December 31, 2017. The shares are considered to be a fully earned, nonrefundable, non-apportionable and non-ratable retainer as consideration for undertaking the agreement. In addition, the Company will pay the consultant $5,000 per month in cash for the term of the agreement. On May 25, 2017, the Company entered into a 20-month consulting agreement with a third party advisory firm for consideration of 20,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.70 per share or $154,000, which will be amortized over the length of the agreement. For the year ending December 31, 2017, the Company has recorded $56,138 in consulting expense related to this agreement. A total of $97,862 remains to be recognized over the remaining service period. As of December 31, 2017 and 2016, the Company had 12,825,393 and 12,587,053 shares of Common Stock issued and 12,666,704 and 12,587,053 shares outstanding, respectively. Potentially Dilutive Securities On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of December 31, 2016 (See Note 11). On January 1, 2017 the Company granted 25,000 options to an employee of the Company as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 25,000 options fully vested as of December 31, 2017. (See Note 11). On January 3, 2017 the Company granted 12,000 options to an employee of the Company as compensation for being appointed as a consultant of the Company. The options have an exercise period of five years with an exercise price of $2.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of December 31, 2017 (See Note 11). Sales Pursuant to Regulation S On April 7, 2017, the Company issued shares of common stock and warrants pursuant to a private placement conducted under the exemptions from registration under Regulation S. Each unit sold to investors consists of $35,000 face value purchase price of 5,000 shares plus warrants to purchase the number of equivalent shares. The Company retains the right to accept less than the $35,000 face value from any investor at its discretion. The Company has entered into the following subscription agreements: On April 10, 2017, the Company sold 4,580 shares at $7.00 per share for a total purchase price of $32,060 to a private investor. The investor also received 4,580 warrants that were valued using the Black Scholes valuation model to have a fair value of $2,375 (See Note 11). On April 26, 2017, the Company sold 4,670 shares at $7.00 per share for a total purchase price of $32,690 to a private investor. The investor also received 4,670 warrants that were valued using the Black Scholes valuation model to have a fair value of $1,521 (See Note 11). On May 16, 2017, the Company sold 790 shares at $7.00 per share for a total purchase price of $5,530 to a private investor. The investor also received 790 warrants that were valued using the Black Scholes valuation model to have a fair value of $130 (See Note 11). On July 21, 2017, the Company sold 4,300 shares at $5.00 per share for a total purchase price of $21,500 to a private investor. The Company did not grant any warrants to the investor under this agreement. No options, warrants or other potentially dilutive securities other than those disclosed above have been issued as of December 31, 2017 and 2016.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 5 - INCOME TAXES	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2017 and 2016 is as follows: 12/31/2017 12/31/2016 US Income before income taxes $ (6,209,768 ) $ (592,288 ) Taxes under statutory US tax rates $ (2,111,321 ) $ (201,378 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 156,724 $ 193,451 Foreign tax rate differential $ 424,810 $ 19,122 Tax Cuts and Jobs Act $ 181,881 $ - Permanent differences $ 1,384,635 $ 360 State taxes $ (31,629 ) $ (11,594 ) Income tax (expense) income $ 5,100 $ (39 ) The decrease in the Company's effective tax rate in the previous years was primarily attributable to The Tax Cuts and Jobs Act (the “Act”), which was enacted on December 22, 2017. The Act reduces the U.S. federal corporate income tax rate from 34% to 21%. The most significant impact of the legislation for the Company was a $181,881 reduction of the value of net deferred tax assets (which represent future tax benefits) as a result of lowering the U.S. corporate income tax rate from statutory rate of 34% to 21%. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities consist of the following: 12/31/2017 12/31/2016 US Net operating loss carry forward $ 399,115 $ 329,848 Greece Net operating loss carry forward 53,177 176,443 Cyprus Net operating loss carry forward 11,274 11,052 United Kingdom Net operating loss carry forward 50,772 11,052 Total deferred tax asset 514,338 517,343 Valuation allowance (514,338 ) (517,343 ) Deferred tax asset, net $ - $ - At December 31, 2017, the Company had U.S. net operating loss carry forwards of approximately $1,504,390 that may be offset against future taxable income, subject to limitation under IRC Section 382, which begin to expire in 2031. At December 31, 2017, the Company had Greece net operating loss carry forwards of approximately $183,369 that may be offset against future taxable income which begin to expire in 2019. At December 31, 2017, the Company had United Kingdom net operating loss carry forwards of approximately $406,172 that may be offset against future taxable income part or all of which may not be available to offset our future taxable income in the United Kingdom should there be a change in the nature or conduct of our business in the United Kingdom within the three years subsequent to the date of our acquisition of Decahedron. During the period ending December 31, 2017, the Company generated Cyprus net operating loss carry forwards of $90,194 which may be carryforward for five (5) years. The Company does not anticipate to generate taxable income in Cyprus in excess of its Cyprus net operating losses. No tax benefit has been reported in the December 31, 2017 or 2016 consolidated financial statements due to the uncertainty surrounding the realizability of the benefit, based on a more likely than not criteria and in consideration of available positive and negative evidence. The Company asserts that it will indefinitely reinvest the unremitted earnings and profits generated by Amplerissimo, its Cyprus subsidiary, in 2015. Accordingly, no U.S. deferred tax liability has been established for the unremitted earnings and profits generated in Cyprus. The Company applied the "more-likely-than-not" recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2017 and December 31, 2016, respectively. The Company has elected to classify interest and penalties that would accrue according to the provisions of relevant tax law as interest and other expense, respectively. As of December 31, 2017 the Company has accrued approximately $86,409 in other expense. The Company's tax years since inception through 2017 remain open to examination by most taxing authorities. Taxes payable are $1,358,789 and $1,080,590 as of December 31, 2017 and December 31, 2016, respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 6 - RELATED PARTY TRANSACTIONS	On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in Common Stock and Additional Paid in Capital). DOC Pharma S.A. As of December 31, 2017 and 2016, the Company has a prepaid balance of €776,431 ($933,425) and an accounts payable balance of €133,756 ($160,801), resulting in a net prepaid balance, related to purchases of inventory, of €642,675 ($772,623) in the year ended December 31, 2017 to DOC Pharma S.A. As of December 31, 2016, the Company had a prepaid balance of €65 ($69) to DOC Pharma S.A. The Company’s CEO, Mr. Grigorios Siokas’, wife is the managing director of DOC Pharma and Mr. Siokas himself served as a principal of DOC Pharma. During the years ended December 31, 2017 and 2016, the Company has purchased a total of €4,733,375 ($5,349,187) and €2,906,785 ($3,218,392), respectively, of products from DOC Pharma, respectively. During the years ended December 31, 2017 and 2016, respectively, the Company had $0 and €176,456 ($195,372) revenue from DOC Pharma On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with DOC Pharma S.A, pursuant to which DOC Pharma S.A., paid existing bills of the Company in the amount of €12,000 ($12,662), excluding the Vendor Bills. The loan bears an interest rate of 2% per annum and was due and payable in full on October 31, 2016. As of December 31, 2017, the Company has an outstanding principal balance under this note of €12,000 ($14,426) and accrued interest expense of $572. Medihelm S.A As of December 31, 2017, the Company has an outstanding payable balance due to Medihelm S.A of €320,650 ($385,485). Medihelm’s managing director is the mother of Nikolaos Lazarou, the director of Decahedron. Additionally, the Company has a receivable balance of €142,564 ($171,390) and a prepaid balance, related to purchases of inventory, of €1,623,980 ($1,952,349) as of December 31, 2017. During the year ended December 31, 2017, SkyPharm purchased €9,027,639 ($10,202,135) and Decahedron purchased £605,709 ($784,272) of products from Medihelm. SkyPharm generated revenue from Medihelm of €1,265,184 ($1,429,784). During the year ended December 31, 2016, the SkyPharm made purchases of €633,975 ($701,937) of products from Medihelm and had revenue from Medihelm of €134,977 ($149447). Grigorios Siokas During the year ended December 31, 2015, the Company borrowed €10,000 ($10,906) as a loan payable from Mr. Grigorios Siokas. The loan has no formal agreement and bears no interest. During the year ended December 31, 2016, the Company repaid a total of €10,000 ($10,552) resulting in full repayment of this loan. On October 1, 2016, the Company borrowed €5,000 ($5,276) from Mr. Siokas, CEO, related to its subsidiary’s purchase of additional capital of SkyPharm. The loan is non-interest bearing and has a maturity date of October 1, 2017. During the year ending December 31, 2017, the Company borrowed an additional €1,000 ($1,202). The outstanding balance as of December 31, 2017 was €6,000 ($7,213). During the year ended December 31, 2016, the Company borrowed €90,500 ($95,496) as additional loans payable from Mr. Siokas. During the year ended December 31, 2017, the Company borrowed an additional €623,621 ($749,717). These loans have no formal agreements and bear no interest. As of December 31, 2017, the Company paid back the entire outstanding balance of the loans or €714,121 ($858,516). As of December 31, 2017 and 2016, the Company has recorded €0 ($0) and €14,646 ($15,454), respectively in prepayments to Mr. Siokas for board of directors’ fees. During the year ended December 31, 2017, Mr. Siokas returned the €14,646 ($17,607) that was prepaid to him and was paid total compensation of $250,000. Ourania Matsouki During the year ended December 31, 2016, the Company borrowed €44,995 ($47,479) from Mrs. Matsouki, Greg Siokas, CEO, wife. During the year ended December 31, 2017, the Company borrowed an additional €55,000 ($66,121). These loans have no formal agreement and bear no interest. As of December 31, 2017, the Company paid back the outstanding balance of €99,995 ($120,214) of these loans. Dimitrios Goulielmos On November 21, 2014, SkyPharm entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company, pursuant to which the Company borrowed €330,000 ($401,115) from Mr. Goulielmos. The Loan bears an interest rate of 2% per annum and was due and payable in full on May 11, 2015. On November 4, 2015, €130,000 ($142,860) in principal and the related accrued interest of €733 ($806) was forgiven and the remaining balance of €200,000 will no longer accrue interest as part of the stock purchase agreement with Grigorios Siokas on November 4, 2015 referenced above. As of December 31, 2016, €60,000 ($63,312) of the loan was paid back. During the year ended December 31, 2017 an additional €70,500 ($84,755) was paid back and a principal balance of €69,500 ($83,553) and €0.00 of accrued interest remains. In connection with the Decahedron SPA, on February 9, 2017, Decahedron, Medihelm S.A. and Nikolaos Lazarou entered into a liability transfer agreement whereby the loan previously provided Decahedron to the Mr. Lazarou prior to the acquisition would be cancelled in exchange for Mr. Lazarou’s personal assumption of approximately £172,310 ($233,118) owed to MediHelm S.A., a creditor of Decahedron. On December 19, 2017, the Company entered into a stock purchase agreement with an officer and director of the Company, whereby for consideration of €80,000 ($94,495) the Company purchased 20,000 shares of its common stock. As per the agreement, the sale and transfer of the shares occurred on December 19, 2017, the date of signing, however the Company is entitled to pay the full consideration in tranches until July 2018. As of December 31, 2017, the Company has paid consideration of €28,000 ($33,073) and has an amount due to related party of €52,000 ($61,422) recorded as accounts payable related party as of December 31, 2017. The shares were returned to the Company in February 2018. As of the date of this filing, the Company has paid an additional consideration of €32,000 ($38,470) and has an amount due to related party of €20,000 ($24,044). Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 7 - CONVERTIBLE DEBT	November 15, 2017 Securities Purchase Agreement On November 15, 2017, the Company entered into a Securities Purchase Agreement with certain third party investors (the “Buyers”), pursuant to which the Company has agreed to issue for a purchase price of $3,000,000, $3,350,000 in aggregate principal amount of Senior Convertible Notes (the “Notes”) to the Buyers, convertible into 670,000 shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) and warrants to purchase an aggregate of 536,000 shares of Common Stock (the “Warrants”.) The Notes contained an original issue discount of $350,000. Of the $3,000,000 purchase price, $240,000 went directly to financing costs (see below) and $74,000 went directly to legal fees such that the Company received net proceeds of $2,686,000. The Notes provide that the Company will repay the principal amount of the Notes in equal monthly installments beginning on January 1, 2018 and repeating on the first business day of each calendar month thereafter until the fourteenth month anniversary date of issuance (each a “Installment Date”), and, subject to the Blocker (as defined below), the Company shall pre-deliver up to 670,000 shares of Common Stock to the Buyers in connection therewith (the “Pre-Delivery Shares”). Eighty-five (85%) percent of any cash proceeds received by the Buyers from the sale of Pre-Delivery Shares shall be applied against the particular installment amount due on such Installment Date under the Note. No interest will accrue under the Notes unless and until an Event of Default (as defined) has occurred and is not cured. As of December 31, 2017 and as of the date of filing, no such event of default has occurred and no shares have been issued. The Notes are convertible at any time by the Holder into shares of Common Stock at the rate of $5.00 per share. In the event of an issuance of Common Stock for a consideration less than the Conversion Price (other than Excluded Securities, as defined) the Conversion Price shall be reduced to the price of the dilutive issuance, (the “Conversion Price”). Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the “VWAP”). The Company valued the beneficial conversion feature at intrinsic value and has recorded $1,140,711 to debt discount, which will be amortized over the life of the Notes. The Notes are senior in right of payment to all existing and future indebtedness of the Company except Permitted Indebtedness (as defined in the Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions. The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Warrants have a five-year term and are exercisable into 536,000 shares of Common Stock beginning May 16, 2018 or six months after the issue date. The Warrants are exercisable at $7.50 per share subject to full ratchet anti-dilution protection (see above). As of December 31, 2017 and through the date of filing, there were no anti-dilution trigger events. The Warrants will be exercisable on a cashless basis if a registration statement is not effective covering the resale of the underlying Warrant Shares. The Company calculated the warrants at relative fair value of $1,545,288, which was recognized as a discount to the Notes and is being amortized as interest expense over the remaining term of the Notes. Conversion of the Notes and exercise of the Warrants are each subject to a blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company’s issued and outstanding Common Stock (each, a “Blocker”). The Company filed, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the “Registration Rights Agreement”). As a condition to the closing of the Financing, each Buyer, severally, will be required to execute a leak-out agreement (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company’s Common Stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double. On November 15, 2017 in connection with the $3,350,000 Securities Purchase Agreement, Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for the transaction equal to eight (8%) percent of the total gross proceeds of the offering, or $240,000 and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors), or 53,600 shares; and, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six months after the issue date or May 16, 2018 and were valued at a fair value of $386,003 which was fully expensed during the year ending December 31, 2017. The $240,000 cash commission was recorded as debt discount and will be amortized over the term of the Notes. During the year ended December 31, 2017, there were no principal conversions and the Company repaid principal in the amount of $239,286, such that the remaining outstanding principal balance of the Notes as of December 31, 2017 is $3,110,714. The Company recorded a total of $3,350,000 of debt discounts related to the above Notes during the year ended December 31, 2017. The debt discounts are being amortized over the term of the debt. Amortization of the debt discounts for the year ended December 31, 2017 was $360,890.

DEBT

DEBT	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 8 - DEBT	On March 4, 2015, the Company entered into a $9,000 Loan Agreement with Mr. Angelo Drakopoulos, pursuant to which Mr. Drakopoulos paid a $9,000 outstanding bill on behalf of the Company. The loan bears an interest rate of 8% per annum and was due and payable in full on May 5, 2016. As of December 31, 2017, the Company has repaid the principal balance under this note of $9,000 and the related accrued interest expense of $1,463 in full. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,812), of which proceeds of €10,000 ($10,906) have been received as of December 31 2016. The loan bears an interest rate of 1% per annum and was due and payable in full on November 5, 2016. The Company repaid €2,000 ($2,110) as of December 31, 2016. During the year ended December 31, 2017, the Company repaid the outstanding balance of €8,000 ($9,618) and accrued interest of €115 ($138) in full and reversed the €10,000 ($12,022) receivable that was never received. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €80,000 ($87,248) of which proceeds of €70,000 ($76,342) have been received as of December 31, 2016. The loan bears an interest rate of 5% per annum and was due and payable in full on November 5, 2016. As of December 31, 2016, the outstanding balance was €65,000 ($68,588). During the year ended December 31, 2017, the Company repaid €55,000 ($66,121) of principal and €3,400 ($4,087) in accrued interest in full and also reversed the €10,000 ($12,022) receivable that was never received. On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($43,624) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. During the year ended December 31, 2017, the Company repaid €17,000 ($20,437) of principal and €2,060 ($2,477) of accrued interest in full. During the year ended December 31, 2015, the Company borrowed €30,000 ($32,718) as a loan payable from Mr. Panagiotis Drakopoulos, former Director and former Chief Executive Officer. The loan had no formal agreement and bore no interest. During the year ended December 31, 2016, the Company repaid €13,000 ($13,718) of the loan. During the year ended December 31, 2017 the Company repaid the remaining €17,000 ($20,437) in full. During the year ended December 31, 2015, the Company borrowed €30,000 ($32,718) from a third party. There was no formal agreement and the loan bore no interest. During the year ended December 31, 2016 the Company repaid the €30,000 ($31,656) loan in full. On January 6, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €150,000 ($158,280). The loan bore an interest rate of 1% per annum and is due and payable in full on February 6, 2016. As of December 31, 2016, the Company repaid the loan in the amount of €150,000 ($158,280) and accrued interest of €458 ($483) in full. On February 5, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,104). The loan bore an interest rate of 6% and had no maturity date. During the year ended December 31, 2017, the Company repaid the €20,000 ($24,044) loan and accrued interest of €1,020 ($1,226) in full. On March 4, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760) from a third party. On May 04, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed an additional €50,000 ($52,760). The loans bore an interest rate of 6% and a maturity date of March 4, 2017 and May 4, 2017, respectively. During the year ended December 31, 2017, the Company repaid both loans in the amount of €100,000 ($120,220) and accrued interest of €1,175 ($1,413) in full. On April 19, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €100,000 ($105,520). The loan bore an interest rate of 6% and matured on April 19, 2017. During the year ended December 31, 2017, the Company repaid the loan in the amount of €100,000 ($120,220) and accrued interest of €3,100 ($3,727) in full. On April 22, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €38,000 ($40,098). The loan bore an interest rate of 6% and matured on April 22, 2017. During the year ended December 31, 2017, the Company repaid the loan in the amount of €38,000 ($45,684) and accrued interest of €1,777 ($2,136) in full. On May 24, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760). The loan bore an interest rate of 6% and matured on May 24, 2017. During the year ended December 31, 2017, the Company repaid the principal balance of €50,000 ($60,110) and accrued interest of €1,275 ($1,533) in full. On October 18, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €10,000 ($10,552). The loan bore an interest rate of 10% and will mature on October 18, 2017. During the year ended December 31, 2017, the Company repaid the principal balance of €10,000 ($12,022) and accrued interest of €545 ($655) in full. Loan Facility Agreement On August 4, 2016, the Company’s wholly owned subsidiary SkyPharm entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the “Loan Facility” the “Lender”). The Loan Facility initially provided SkyPharm with a credit facility of up to $1,292,769 (€1,225,141). Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the Lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement as amended is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. On September 13, 2016, SkyPharm entered into a First Deed of Amendment with the Loan Facility increasing the maximum loan amount to $1,533,020 as a result of the Lender having advanced $240,251 (€227,629) to SkyPharm. On March 23, 2017, SkyPharm entered into an Amended and Restated Loan Facility Agreement (the “A&R Loan Facility”), with the Loan Facility which increased the loan amount to an aggregate total of $2,664,960 (€2,216,736) as a result of the lender having advanced $174,000 (€164,898) in September 2016, $100,000 (€94,769) in October 2016, $250,000 (€236,922) in November 2016, $452,471 (€428,800) in December 2016, $155,516 (€129,360) in January 2017, $382,327 (€318,023) in July 2017 and $70,000 (€58,227) in December 2017. The A&R Loan Facility amends and restates certain provisions of the Loan Facility Agreement, dated as of August 4, 2016, by and among the same parties. Advances under the A&R Loan Facility continue to accrue interest at a rate of 10% per annum from the applicable date of each drawdown and require quarterly interest payments. The A&R Facility now permits prepayments at any time. The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018. The A&R Loan Facility is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas (the “Pledged Shares”). The A&R Loan Facility was also amended to provide additional affirmative and negative covenants of Sky Pharm and the Guarantor during the term of loans remain outstanding, including, but not limited to, the consent of the Lender in connection with (i) the Company or any of its subsidiaries incurring any additional indebtedness; or (ii) in the event of any increase in the Company’s issued and outstanding shares of Common Stock, the Pledged Shares shall be increased to an amount equal to a minimum of ten percent (10%) of the issued and outstanding shares of the Company. As of December 31, 2017, the outstanding balance under this note was $3,117,287 (€2,592,986) and accrued interest expense of $221,657 (€184,376) has been recorded. As of December 31, 2017 and 2016, the Company recorded €35,060 ($42,149) and €120,000 ($126,624) in debt discounts, respectively, related to this note. The debt discounts are being amortized over the term of the debt. During the year ended December 31, 2016 the Company amortized a total of €13,103 ($14,507). Amortization of the debt discounts for the year ended December 31, 2017 was €78,154 ($88,322). Bridge Loans On March 16, 2017 and March 20, 2017, SkyPharm entered into loan agreements with the Synthesis Peer-To Peer-Income Fund (the “Bridge Loans”). The Bridge Loans provided to SkyPharm loans of €41,590 ($50,000) and €100,000 ($120,220), respectively. The Bridge Loans accrue interest at a rate of 10% per annum and were repayable on April 16, 2017 and April 20, 2017, respectively, together with all other amounts then accrued and unpaid. On April 16, 2017, the maturity dates were amended for no additional consideration or change in terms and conditions. The maturity dates of both loans were amended, and they matured on May 16, 2017 and May 20, 2017, respectively. The Company has accrued interest expense of an aggregate total of €10,690 ($12,851) for both loans and the outstanding balances of these loans was €41,590 ($50,000) and €100,000 ($120,220), respectively, as of December 31, 2017. On May 5, 2017, SkyPharm entered into a loan agreement with Synthesis Peer-To-Peer Income Fund for €28,901 ($34,745). The loan accrues interest at a rate of 10% per annum and matured on September 30, 2017. The Company has accrued interest expense of €1,908 ($2,294) and the outstanding balance on this loan was €28,901 ($34,745) as of December 31, 2017. Trade Facility Agreements On April 10, 2017, Decahedron entered into a Trade Finance Facility Agreement (the “Decahedron Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The Decahedron Facility provides the following material terms: · The Lender will provide Decahedron a facility of up to €2,750,000 ($3,306,050) secured against Decahedron’s receivables from the sale of branded and generic pharmaceutical sales. · The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. · The term of the Decahedron Facility will be for 12 months. · The obligations of Decahedron are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. · The Lender has the right to make payments directly to Decahedron’s suppliers. · The following fees should be paid in connection with the Decahedron Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The current draw on the Decahedron Facility is $0. On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The SkyPharm Facility provides the following material terms: · The Lender will provide SkyPharm a facility of up to €2,000,000 ($2,404,400) secured against SkyPharm’s receivables from the sale of branded and generic pharmaceutical sales. In the event that accounts receivable becomes uncollectible, the Company will be obligated to pay back the notes in full. · The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. · The term of the SkyPharm Facility will be for 12 months. · The obligations of SkyPharm are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. · The Lender has the right to make payments directly to SkyPharm’s suppliers. · The following fees should be paid in connection with the SkyPharm Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The current draw on the SkyPharm Facility is €5,596,910 ($6,728,606) and the Company has accrued €312,828 ($376,082) in monthly fees related to this agreement. The Company obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the Lender. On November 16, 2017, SkyPharm signed an amended agreement with Synthesis Structured Commodity Trade Finance Limited that increased the maximum aggregate facility limit from €2,000,000 ($2,404,400) to €6,000,000 ($7,213,200). All other terms of the original agreement remain the same. The Company has recorded a total debt discount of €104,338 ($125,435) in origination fees associated with these loans, which will be amortized over the term of the agreements. Amortization of debt discount for year ended December 31, 2017 was €61,295 ($69,269). None of the above loans were made by any related parties.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 9 - COMMITMENTS AND CONTINGENCIES	Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of December 31, 2017, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations. Operating Leases The Company conducts its operations from an office located in Chicago, Illinois for which beginning in January 2015, the monthly rent expense is $709, which has been paid through December 31, 2017. The lease expired as of May 31, 2017, however, the Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019. Rent expense for the years ended December 31, 2017 and 2016, was $8,502 and $4,960, respectively. The offices of Amplerissimo are located a t 9, Vasili, Michaelidi Street, 3026, Limassol, Cyprus. The Company had a one-year lease which commenced on July 29, 2013 and was last renewed through July 2018, at the rate of €110 ($124) per month. Rent expense for the years ended December 31, 2017 and 2016 was €1,320 ($1,492) and €1,320 ($1,462), respectively. The offices of SkyPharm are located at 5, Agiou Georgiou Street 57001, Pylaia, Thessaloniki, Greece. The Company has a six-year lease that commenced on September 1, 2014 at the rate of €4,325 ($4,802) per month. In December 2015, the lease was revised to include an additional rental of the first floor at a rate of €800 ($886) per month. The lease was further revised in March 2016 to include another additional rental of the first floor at a rate of €800 ($886) per month beginning in May 2016. On May 30, 2016, the lease was revised again to include an additional rental of space at a rate of €1,825 ($2,021) per month beginning in June 2016. On March 23, 2017, SkyPharm entered into an additional three year lease at a rate of €1,250 per month that commenced May 2017As a result, the total monthly lease amount is now €7,750 ($8,758) per month. Rent expense for the years ended December 31, 2017 and 2016 was €103,000 ($116,400) and €80,675 ($89,323) respectively. The offices of Decahedron are located at Unit 11, Spire Greene Centre, Harlow, CM19 5TR, Essex, U.K., for which we pay approximately ₤1,908 ($2,470) per month, under an amendment to a lease dated October 25, 2011, which commenced on October 25, 2016 and expires on October 24, 2021. Rent expense from the date of acquisition through December 31, 2017 was ₤20,992 ($27,180). Future minimum operating lease commitments consisted of the following at December 31, 2017: Year Ended December 31, Amount (USD) 2018 $ 170,394 2019 $ 164,463 2020 $ 74,255 2021 $ 25,813 2022 $ - Thereafter $ - $ 434,925 Intellectual Property Sale Agreement On October 1, 2016, the Company entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou (the “IPSA”) for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related thereto (the “Intellectual Property”). The IPSA provides that the sellers shall be entitled to an aggregate of 200,000 shares of common stock of the Company, none of which have been issued to date, and issuable as follows in equal parts to each seller: · 50,000 shares upon the successful conclusion of Preclinical Trials. · 50,000 shares upon the conclusion of Phase I testing. · 50,000 shares upon the conclusion of Phase II testing. · 50,000 shares upon the conclusion of Phase III testing. The Company has agreed to pay Anastasios Tsekas €1,500 per month until the first issuance of the shares referenced above. The Company has also agreed that in the event the Company disposes of the Intellectual Property prior to the periods referenced above, the sellers shall be entitled to the issuance of all the shares referenced above. The Company is in the process of locating a suitable lab to conduct the preclincal trial phase, which has not yet begun as of the date of filing. Letter of Intent On June 21, 2017, the Company signed a new Letter of Intent (LOI) to acquire the outstanding shares of CC Pharma GmbH, a leading re-importer of EU pharmaceuticals to Germany. Under the terms of the LOI, Cosmos Holdings holds the exclusive right to complete its due diligence process and complete the transaction by October 31, 2017. In connection with the non-binding LOI, the Company is required to pay a non-refundable fee of €400,000 ($454,800) to the shareholders of CC Pharma GmbH in connection with the costs of due diligence and the exclusive right to negotiate the terms of the definitive agreements. On July 6, 2017, the Company paid the €400,000 ($454,800) to CC Pharma GmbH and the Company has recorded an expense of €400,000 ($454,800) for the year ended December 31, 2017. The Company did not enter into any definitive agreements by December 31, 2017 and is currently negotiating with CC Pharma for an extension. The Company makes no assurances that the parties will enter into any definitive agreements in the future. Placement Agreement On August 8, 2017, the Company entered into an agreement with a third party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering. As of the year ended December 31, 2017 through the date of filing, there have been no such placements made.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 10 - EARNINGS PER SHARE	Basic net income (loss) per share is computed by dividing net income (loss) attributable to the Company, decreased with respect to net income or increased with respect to net loss by dividends declared on preferred stock by using the weighted-average number of common shares outstanding. The dilutive effect of incremental common shares potentially issuable under outstanding options, warrants and restricted shares is included in diluted earnings per share in 2017 and 2016 utilizing the treasury stock method. The computations of basic and diluted per share data were as follows: 12/31/2017 12/31/2016 Numerator for Basic and Diluted Earnings Per Share: Net (loss) income $ (6,209,768 ) $ (601,002 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 12,780,813 12,564,824 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 12,780,813 12,564,824 Basic and Diluted Net (Loss) Income per Share (0.49 ) (0.05 ) The following table summarized the potential shares of Common Stock that were excluded from the computation of diluted net loss per share for the years ended December 31, 2017 and 2016 as such shares would have had an anti-dilutive effect: 2017 2016 Common Stock Warrants 38,824 - Common Stock Options 16,240 80,741 Convertible Debt 622,142 - Total 677,206 80,741

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 11 - STOCK OPTIONS AND WARRANTS	On January 5, 2013, the Company granted 96,000 options to a former director, 72,000 of which were forfeited in a subsequent period. The options have an exercise period of four years with an exercise price of $1.00. In the event that the former director ceases to serve on the Board of Directors for any reason, the Director is entitled to a pro-rata portion of the annual options. The options were valued at $43,151 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $1.80; Exercise price: $1.00; Option term: 4 years; Computed volatility: 448%. On November 4, 2016, the Board of Directors authorized the exercise of stock options held by the former director to purchase 24,000 shares of common stock. On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of December 31, 2016. The options were valued at $65,290 using the Black Sholes Option Pricing Model with the following inputs: stock price on measurement date: $5.80; Exercise price: $2.00; Option term: 4 years; Computed volatility: 159%. The Company expensed $16,636 as of December 31, 2016. During the year ended December 31, 2017 the Company has expensed an additional $48,655. On January 1, 2017 the Company entered into an agreement whereby the employee was granted compensation of €1,000 per month and an annual retainer of 25,000 stock options as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 25,000 options fully vested as of December 31, 2017. The options were valued at $195,307 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $8.20; Exercise price: $1.00; Option term: 4 years; Computed volatility: 136.76%. The fair value of the options will be amortized over a year with $195,307 expensed during the year ended December 31, 2017. On January 3, 2017 the Company determined to create an advisory board and appointed Mr. Orestes Varvitsiotes as its first member. Mr. Varvitsiotes is a registered broker dealer who is currently engaged with Aegis Capital Corp. In connection therewith, the Company entered into an Advisory Board Member Consulting Agreement, dated as of January 3, 2017 whereby an annual retainer of 12,000 stock options was granted as compensation for services. The options have an exercise period of five years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 12,000 options fully vested as of December 31, 2017. The options were valued at $94,830 using the Black Scholes Option Pricing Model, with the following inputs: stock price on measurement date: $8.20; Exercise price: $2.00; Option term: 5 years; Computed volatility: 155.37%. The fair value of the options will be amortized over the year with $94,830 expensed during the year ended December 31, 2017. A summary of the Company’s option activity during the year ended December 31, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2015 24,000 $ 1.00 1.02 $ - Granted 12,000 2.00 4.00 - Forfeited - - - - Exercised (24,000 ) 1.00 - - Expired - - - - Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ - Granted 37,000 1.32 3.33 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 49,000 $ 1.49 3.19 $ 426,800 Exercisable, December 31, 2017 49,000 $ 1.49 3.19 $ 426,800 In connection with a private placement that took place on April 7, 2017, the Company issued warrants for a total of 10,040 common shares of the Company at a 1:1 ratio for shares purchased by investors (See Note 4). The warrants were valued using the Black Scholes valuation model with stock prices ranging from $7.60 to $8.50, exercise price of $30.00, volatility ranging from 76.66% to 90.86% based on the Company’s stock price, an expected term of 1 year and a risk free rate ranging from 1.07% to 1.11%. On November 16, 2017, in connection with the Securities Purchase Agreement, the Company issued warrants for 536,000 common shares of the Company (See Note 7). The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $7.20, exercise price of $7.50, volatility of 169.29% based on the Company’s stock price, an expected term of 5 years and a risk free rate of 1.68%. The relative fair value of the warrants of $1,545,288 was recorded as a discount to the Notes and as additional paid in capital and the expense will be amortized over the two-year term of the underlying Notes. The warrants will become exercisable on May 16, 2018. On November 16, 2017 in connection with the $3,350,000 Securities Purchase Agreement (See Note 7), Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, was issued warrants for 53,600 common shares of the Company. The fair value of the warrants was determined using a Black Scholes valuation model with a stock price of $7.20, exercise price of $5.00, volatility of 169.29% based on the Company’s stock price, an expected term of 5 years and a risk free rate of 1.68%. The value of the warrants of $368,003 was recognized as interest expense during the year ended December 31, 2017. The warrants will become exercisable on May 16, 2018. The significant assumptions used to determine the fair values of warrants issued, using a Black-Scholes valuation model are as follows: December 31, 2017 December 31, 2016 Market value of underlying stock $7.20-$8.50 - Volatility 76.66%-169.29% - Expected term (in years) 1 – 5.5 - Risk-free interest rate 1.07% - 1.68% - Expected dividend yield None - A summary of the Company’s warrant activity for the years ending December 31, 2017 and 2016 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2015 - $ - - $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2016 - $ - - $ - Granted 599,640 7.65 5.29 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 599,640 $ 7.65 5.29 $ 1,725,921 Exercisable, December 31, 2017 10,040 $ 30.00 .30 $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 12 - SUBSEQUENT EVENTS	Amendment and Exchange of Agreements On February 20, 2018, Cosmos Holdings, Inc. (the “Company”) entered into two separate Amendment and Exchange Agreements (each, an “Exchange Agreement”), each by and between the Company and an institutional investor that previously purchased a Senior Convertible Note from the Company on November 16, 2017 (each, an “Existing Note”) pursuant to a Securities Purchase Agreement, dated as of November 15, 2017, by and between the Company and such holders of Existing Notes (the “Securities Purchase Agreement”). Pursuant to each Exchange Agreement, the Company issued a new senior convertible note (each, a “New Note”) in the amounts of $2,791,668 and $558,332 to each holder for a total aggregate principal amount of $3,350,000 in exchange for an Existing Note. Each New Note is identical in all material respects to the Existing Note, except that (i) the New Note shall not be convertible into shares of the Company’s common stock (the “Common Stock”) until April 20, 2018, (ii) all future cash installment payments under such New Note will be made at a redemption price equal to 112% of the applicable installment amount, (iii) the Company’s existing obligation to initially deliver predelivery shares of its common stock to the holder of such New Note is deferred until April 20, 2018 and (iv) at any time on or before June 20, 2018, the Company has the right, at its option, to redeem all, or any part, of the amounts then outstanding under such New Note in cash at redemption price equal to 125% of such amounts then outstanding under such New Note. Except as set forth in the Exchange Agreements and the New Notes, the Securities Purchase Agreement and each of the other transaction documents that were executed in connection with the Securities Purchase Agreement remain unchanged and in full force and effect. Third Party Loan Agreement On March 16, 2018, the Company entered into a loan facility agreement, with a third party, pursuant to which the Company received €1,500,000 ($1,845,072). The loan bears an annual interest rate of 4.7%, is unsecured and matures on March 16, 2019. Related Party Loan from Director On March 14, 2018 and March 16, 2018, the Company borrowed €300,000 ($371,383) and €200,000 ($246,010), respectively from Mr. Grigorios Siokas, Chief Executive Officer. These loans have no formal agreements, bear no interest and have no maturity dates. The proceeds will be used by the Company for working capital. Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was recently formed to be a global supplier of Cannabis, cannabidiol (CBD) and/or any Cannabis Extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of this Agreement. Following a thirty (30) day due diligence period, and subject to satisfactory due diligence of the Company, Marathon shall: (a) grant the Company a 33 1/3% equity interest in Marathon as partial consideration for the Company’s distribution services; and (b) make a cash payment of CAD $2,000,000 to the Company, subject to repayment by the Company in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon Board of Directors. On April 19, 2018, the Company and Marathon amended the Distribution Agreement to provide for Marathon to conduct due diligence on the Company until May 10, 2018. The Company shall continue to provide confidential information even after the initial payment of CAD $2,000,000. On April 18, 2018, SkyPharm amended the Loan Facility Agreement with Synthesis Peer-To-Peer Income Fund (the “Loan Facility” and the “Lender”). As of December 31, 2017, the outstanding principal balance under the Loan Facility was $3,117,287 (€2,592,986), excluding interest, of which $136,800 has been paid. Until January 1, 2018, advances under the Loan Facility accrued interest at ten percent (10%) per annum from the applicable date of each drawdown and require quarterly interest payments. The interest rate was restated as of January 1, 2018 to four (4%) percent plus quarterly Libor Payments, plus two (2%) percent default interest on unpaid amounts in addition to the interest rate. The Loan Facility permits prepayment and is due upon the earlier of (i) 75 days following demand of the Lender; or (ii) December 31, 2021, as amended. The Loan Facility is secured by a personal guaranty of Grigorios Siokas which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. On April 18, 2018, SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term, all of which have been pre-paid by SkyPharm for future financing services.

ORGANIZATION AND NATURE OF BU19

ORGANIZATION AND NATURE OF BUSINESS (Policies)	12 Months Ended
	Dec. 31, 2017
Organization And Nature Of Business Policies
Basis of Financial Statement Presentation	The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America.
Principles of Consolidation	Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd, SkyPharm S.A. and Decahedron Ltd. All significant intercompany balances and transactions have been eliminated.
Reclassifications to Prior Period Financial Statements and Adjustments	Certain reclassifications have been made in the Company’s financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income.
Use of Estimates	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2017 and December 31, 2016, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. For the year ended December 31, 2017, the amounts in these accounts were $65,613, $398,841 (the Euro equivalent of which was €331,759) and $27,542 (the British Pound equivalent of which was £20,358). At December 31, 2016, the amounts in these accounts were $3,143 and $19,876 (the Euro equivalent of which was €18,836). Additionally, for the years ended December 31, 2017 and 2016, the Company had cash on hand in the amount of $290,857 and $693,570, respectively.
Account Receivable	Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information.
Tax Receivables	The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiary in Greece, SkyPharm S.A., does not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of December 31, 2017 and 2016, the Company had a VAT net receivable balance of $961,220 and $398,126, respectively, recorded on the balance sheet as other assets.
Inventory	Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.
Fixed Assets	Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years Depreciation expense was $17,370 and $9,448 for the years ended December 31, 2017 and December 31, 2016, respectively.
Intangible Assets	Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At December 31, 2017, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $8,533 and $0 for the years ended December 31, 2017 and 2016, respectively.
Impairment of Long-Lived Assets	In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Goodwill and Intangibles	The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no record goodwill value. As a result of the acquisition of Decahedron, the Company tested and impaired 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the year ended December 31, 2017.
Fair Value Measurement	The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2017. Cash is considered to be highly liquid and easily tradable as of December 31, 2017 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.
Revenue Recognition	We recognize revenue net of the VAT receivable. We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided.
Stock-based Compensation	The Company records stock based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees".
Foreign Currency Translations and Transactions	Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings.
Concentrations of Credit Risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2017 2016 Number of 10% clients 3 2 Percentage of total revenue 49.63 % 52.49 % Percentage of total AR 20.68 % 26.09 %
Income Taxes	The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus, Greece and the United Kingdom of England. The corporate income tax rate in Cyprus is 12.5% and 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in the United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2017 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management's judgment, the position is not more-likely-then-not sustainable upon audit based on the position's technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of December 31, 2017 the Company had no uncertain tax positions recorded in any jurisdiction where it is subject to income tax.
Basic and Diluted Net Income (Loss) per Common Share	Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in years with net income. Basic and diluted loss per share for each of the years ended December 31, 2016 and 2017 is the same due to the anti-dilutive nature of potential common stock equivalents.
Recent Accounting Pronouncements	In July 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-11,“ Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). Part I relates to the accounting or certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down Round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified as equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted and may be applied on a retrospective basis, including in an interim period. The Company early adopted ASU 2017-11 during the year ended December 31, 2017. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The Company does not believe that the adoption of ASU No. 2017-4 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition of assets or a business. ASU No. 2017-01 is effective for the Company’s fiscal year commencing on January 1, 2018. The effect of this guidance is to be applied prospectively and early adoption is permitted. The Company does not believe that the adoption of ASU No. 2017-01 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require lessees to recognize assets and liabilities for the rights and obligations created by most leases on the balance sheet. The changes become effective for the Company’s fiscal year beginning January 1, 2020. Modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, is required with an option to use certain transition relief. The Company expects this ASU will increase its current assets and current liabilities, but have no net material impact on its consolidated financial statements. In July 2015, the Financial Accounting Standards Board issued Simplifying the Measurement of Inventory, Topic 330 (ASU No 2015-11). ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to lower of cost or net realizable value. The new standard is effective for the Company for fiscal years and interim periods beginning after December 15, 2016. The Company adopted this standard in the first quarter of fiscal 2017, applying it prospectively. The adoption of ASU 2015-11 did not have a material impact on the Company's consolidated financial statements. In May 2014, the FASB issued ASU 2014-09-Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. As of January 1, 2018, the Company has adopted the modified retrospective approach in accordance with ASC 606 – Revenue from Contracts with Customers and recognizes revenue at the point in time at which the customer obtains control of the entity and the Company has satisfied its performance obligations. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

ORGANIZATION AND NATURE OF BU20

ORGANIZATION AND NATURE OF BUSINESS (Tables)	12 Months Ended
	Dec. 31, 2017
Organization And Nature Of Business Tables
Schedule of Calculation of Fixed Assets	Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years
Schedule of Concentrations of Credit Risk	Year Ended December 31, Year Ended December 31, 2017 2016 Number of 10% clients 3 2 Percentage of total revenue 49.63 % 52.49 % Percentage of total AR 20.68 % 26.09 %

ACQUISITION OF DECAHEDRON, LTD

ACQUISITION OF DECAHEDRON, LTD (Tables)	12 Months Ended
	Dec. 31, 2017
Acquisition Of Decahedron Ltd Tables
Unaudited allocation of purchase price	Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884
Intangible assets	Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 -
Unaudited Supplemental Pro Forma Data	Years Ended December 31, 2017 2016 Revenues $ 30,206,825 $ 8,756,772 Cost of revenues 28,256,544 8,128,159 Gross profit 1,950,281 628,613 Operating expenses 6,856,585 991,901 Operating loss (4,906,304 ) (363,288 ) Other income (expense) (1,372,288 ) (506,343 ) Income tax (expense) (2,801 ) 30,803 Net Loss $ (6,281,393 ) $ (838,828 ) Other comprehensive loss (343,766 ) 1,940 Comprehensive net loss $ (6,616,159 ) $ (836,888 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes Tables
Schedule of reconciliation of income tax expense	12/31/2017 12/31/2016 US Income before income taxes $ (6,209,768 ) $ (592,288 ) Taxes under statutory US tax rates $ (2,111,321 ) $ (201,378 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 156,724 $ 193,451 Foreign tax rate differential $ 424,810 $ 19,122 Tax Cuts and Jobs Act $ 181,881 $ - Permanent differences $ 1,384,635 $ 360 State taxes $ (31,629 ) $ (11,594 ) Income tax (expense) income $ 5,100 $ (39 )
Schedule of deferred tax assets and liabilities	12/31/2017 12/31/2016 US Net operating loss carry forward $ 399,115 $ 329,848 Greece Net operating loss carry forward 53,177 176,443 Cyprus Net operating loss carry forward 11,274 11,052 United Kingdom Net operating loss carry forward 50,772 11,052 Total deferred tax asset 514,338 517,343 Valuation allowance (514,338 ) (517,343 ) Deferred tax asset, net $ - $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Tables
Schedule of future minimum operating lease commitments	Year Ended December 31, Amount (USD) 2018 $ 170,394 2019 $ 164,463 2020 $ 74,255 2021 $ 25,813 2022 $ - Thereafter $ - $ 434,925

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share Tables
Schedule of Earnings Per Share, Basic and Diluted	12/31/2017 12/31/2016 Numerator for Basic and Diluted Earnings Per Share: Net (loss) income $ (6,209,768 ) $ (601,002 ) Denominator for Basic Earnings Per Share: Weighted Average Shares 12,780,813 12,564,824 Potentially Dilutive Common Shares - - Adjusted Weighted Average Shares 12,780,813 12,564,824 Basic and Diluted Net (Loss) Income per Share (0.49 ) (0.05 )
Schedule of potentially anti-dilutive shares of Common Stock	2017 2016 Common Stock Warrants 38,824 - Common Stock Options 16,240 80,741 Convertible Debt 622,142 - Total 677,206 80,741

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2017
Stock Options And Warrants Tables
Schedule of option activity during the year	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2015 24,000 $ 1.00 1.02 $ - Granted 12,000 2.00 4.00 - Forfeited - - - - Exercised (24,000 ) 1.00 - - Expired - - - - Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ - Granted 37,000 1.32 3.33 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 49,000 $ 1.49 3.19 $ 426,800 Exercisable, December 31, 2017 49,000 $ 1.49 3.19 $ 426,800
Warrants activity valued	December 31, 2017 December 31, 2016 Market value of underlying stock $7.20-$8.50 - Volatility 76.66%-169.29% - Expected term (in years) 1 – 5.5 - Risk-free interest rate 1.07% - 1.68% - Expected dividend yield None -
Warrants	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2015 - $ - - $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2016 - $ - - $ - Granted 599,640 7.65 5.29 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2017 599,640 $ 7.65 5.29 $ 1,725,921 Exercisable, December 31, 2017 10,040 $ 30.00 .30 $ -

ORGANIZATION AND NATURE OF BU26

ORGANIZATION AND NATURE OF BUSINESS (Details)	12 Months Ended
	Dec. 31, 2017
Furniture and Fixtures [Member] | Minimum [Member]
Estimated Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Estimated Useful Life	7 years
Office and computer equipment [Member] | Minimum [Member]
Estimated Useful Life	3 years
Office and computer equipment [Member] | Maximum [Member]
Estimated Useful Life	5 years

ORGANIZATION AND NATURE OF BU27

ORGANIZATION AND NATURE OF BUSINESS (Details 1) - Integer	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Organization And Nature Of Business Details 1
Number of 10% clients	3	2
Percentage of total revenue	49.63%	52.49%
Percentage of total AR	20.68%	26.09%

ORGANIZATION AND NATURE OF BU28

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 21, 2017	Dec. 31, 2017	Dec. 31, 2016	Feb. 10, 2017	Sep. 27, 2013
State or country of incorporation		Nevada
Date of incorporation		Jul. 21, 2009
Reverse stock split, description	the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock.
Revenues		$ 30,013,378	$ 6,755,436
Cost of revenue		28,057,111	6,154,396
Net loss		(6,209,768)	(601,002)
Working capital deficit		(4,192,984)
Accumulated deficit		(7,211,987)	(1,002,219)
Cash equivalents		290,857	693,570
Value added tax receivable		$ 961,220	398,126
Description for periodic inventory system maintenance		A periodic inventory system is maintained by 100% count.
Depreciation expense		$ 17,370	9,448
Intangible asset, useful life		5 years
Amortization of intangible assets		$ 8,533	0
Impairment of goodwill		$ 1,949,884
Impairment of goodwill, percent		100.00%
Amplerissimo Ltd [Member]
Equity ownership percentage					100.00%
Stock Purchase Agreement [Member] | Decahedron Ltd [Member]
Common stock shares reserved				170,000
United States [Member]
Cash equivalents		$ 65,613	3,143
Cyprus, Greece, And Bulgaria [Member]
Cash equivalents		398,841	$ 19,876
United Kingdom [Member]
Cash equivalents		$ 27,542
Cyprus [Member]
Income tax rate		12.50%
Greece [Member]
Income tax rate		29.00%
United Kingdom of England [Member]
Income tax rate		20.00%

ACQUISITION OF DECAHEDRON, LT29

ACQUISITION OF DECAHEDRON, LTD. (Details)	Dec. 31, 2017USD ($)
Intangible assets	$ 50,000
Decahedron Ltd [Member] | Preliminary Allocation as of February 10, 2017 [Member]
Current assets	6,537
Intangible assets	50,000
Other assets	305,400
Total assets acquired	361,937
Liabilities assumed:
Debt	804,819
Total liabilities assumed	804,819
Net assets acquired	(442,882)
Consideration:
Value of Common Stock Issued at Acquisition	1,479,000
Goodwill	1,921,882
Decahedron Ltd [Member] | Allocation Adjustments [Member]
Current assets
Intangible assets
Other assets	(216,562)
Total assets acquired	(216,562)
Liabilities assumed:
Debt	(188,560)
Total liabilities assumed	(188,560)
Net assets acquired	(28,002)
Consideration:
Value of Common Stock Issued at Acquisition
Goodwill	28,002
Decahedron Ltd [Member] | Final Allocation [Member]
Current assets	6,537
Intangible assets	50,000
Other assets	88,838
Total assets acquired	145,375
Liabilities assumed:
Debt	616,259
Total liabilities assumed	616,259
Net assets acquired	(470,884)
Consideration:
Value of Common Stock Issued at Acquisition	1,479,000
Goodwill	$ 1,949,884

ACQUISITION OF DECAHEDRON, LT30

ACQUISITION OF DECAHEDRON, LTD. (Details 1)	12 Months Ended
	Dec. 31, 2017USD ($)
Intangible assets	$ 50,000
Useful Life (Years)	5 years
Licenses [Member]
Intangible assets	$ 50,000	[1]
[1]	(a) U.K Pharmaceutical Wholesale Distribution License

ACQUISITION OF DECAHEDRON, LT31

ACQUISITION OF DECAHEDRON, LTD. (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cost of revenues	$ 28,057,111	$ 6,154,396
Gross profit	1,956,267	601,040
Operating expenses	6,828,588	803,547
Operating loss	(4,872,321)	(202,507)
Income tax (expense)	2,801	769
Other comprehensive loss	(6,544,534)	(545,787)
Decahedron Ltd [Member] | Proforma [Member]
Revenues	30,206,825	8,756,772
Cost of revenues	28,256,544	8,128,159
Gross profit	1,950,281	628,613
Operating expenses	6,856,585	991,901
Operating loss	(4,906,304)	(363,288)
Other income (expense)	(1,372,288)	(506,343)
Income tax (expense)	(2,801)	30,803
Net Loss	(6,281,393)	(838,828)
Other comprehensive loss	(343,766)	1,940
Comprehensive net loss	$ (6,616,159)	$ (836,888)

ACQUISITION OF DECAHEDRON, LT32

ACQUISITION OF DECAHEDRON, LTD. (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)Integershares
Business acquisition, name of acquired entity	DECAHEDRON, LTD
Business acquisition outstanding percentage	100.00%
Number of businesses acquired | Integer	1
Business acquisition outstanding shares value	$ 1,479,000
Business acquisition outstanding shares in exchange | shares	170,000
Adjustment related to other assets and accounts payable	$ 28,002
Impairment of goodwill	$ 1,949,884
Impairment of goodwill, percent	100.00%
Cash acquired on acquisition	$ 40,858
Acquisition [Member]
Revenues	4,221,751
Net Loss	$ 441,553

PREPAID FINANCING COSTS (Detail

PREPAID FINANCING COSTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Sep. 28, 2016
Deferred financing costs	$ 0
Synthesis Management Limited [Member]
Advanced for additional financing		$ 133,725
Advisory fees paid	214,344
Mr. Spyros Papadopoulos [Member]
Advisory fees paid	706,044
Mr. Spyros Papadopoulos [Member] | From August 8, 2016, through December 31, 2017 [Member]
Advisory fees paid	1,137,793
Synthesis Multi-Asset Architecture [Member]
Advisory fees paid	$ 217,406

CAPITAL STRUCTURE (Details Narr

CAPITAL STRUCTURE (Details Narrative) - USD ($)

Apr. 10, 2017

Apr. 07, 2017

Mar. 01, 2017

Nov. 04, 2016

Dec. 19, 2017

Nov. 21, 2017

Jul. 21, 2017

May 25, 2017

May 18, 2017

May 16, 2017

Apr. 26, 2017

May 25, 2017

May 24, 2017

Dec. 31, 2017

Dec. 31, 2016

Feb. 10, 2017

Sep. 27, 2013

Common stock, shares issued

12,825,393

12,587,053

Common stock, shares outstanding

12,666,704

12,587,053

Common stock shares authorized

300,000,000

300,000,000

Preferred stock shares authorized

100,000,000

100,000,000

Common stock value

$ 12,825

$ 12,587

Reverse stock split, description

the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock.

Purchase of treasury stock from officer

(94,495)

Related party accrual for repurchase of shares of common stock

61,422

Reversal of proceeds due from noteholder due to repayment of note

$ 24,044

Post Merger [Member]

Common stock, shares issued

12,558,553

Common stock, shares outstanding

12,558,553

Prior to merger [Member]

Common stock, shares issued

10,000,000

Amplerissimo Ltd [Member] | Prior to merger [Member]

Common stock, shares issued

2,558,553

Tranche [Member]

Purchase of treasury stock from officer

$ 33,073

Related party accrual for repurchase of shares of common stock

61,422

Tranche 1 [Member]

Purchase of treasury stock from officer

38,470

Reversal of proceeds due from noteholder due to repayment of note

$ 24,044

Stock Purchase Agreement [Member] | Third Party Investor [Member]

Purchase of treasury stock, Shares

138,689

Purchase of treasury stock from officer

$ 1,387

Former Director [Member]

Stock options granted

240,000

Proceed from issuance of common stock

$ 24,000

Director [Member] | Stock Purchase Agreement [Member]

Purchase of treasury stock, Shares

20,000

Purchase of treasury stock from officer

$ (94,495)

Potentially dilutive securities [Member] | Employee [Member] | On January 3, 2017 [Member]

Stock options granted

12,000

Exercise period

5 years

Exercise price

$ 2

Stock options vested

12,000

Potentially dilutive securities [Member] | Employee [Member] | On January 1, 2017 [Member]

Stock options granted

25,000

Exercise period

4 years

Exercise price

$ 1

Stock options vested

25,000

Potentially dilutive securities [Member] | Employee [Member] | On October 1, 2016 [Member]

Stock options granted

12,000

Exercise period

4 years

Exercise price

$ 2

Stock options vested

12,000

Potentially dilutive securities [Member] | Private Placement [Member]

Stock options granted

5,000

Common stock value

$ 35,000

Stock options granted fair value

$ 35,000

ArKo European Business & Services [Member] | Consulting agreement Four [Member]

Common stock, shares issued

20,000

20,000

Commencing agreement date

May 25, 2017

Consulting agreement period

20 months

Common stock value

$ 154,000

$ 154,000

Price per share

$ 7.70

$ 7.70

Consultant charges

$ 56,138

Consulting expense yet to be recognized

$ 97,862

$ 97,862

ArKo European Business & Services [Member] | Consulting agreement Three [Member]

Common stock, shares issued

30,000

Commencing agreement date

May 8, 2017

Consulting agreement period

1 year

Common stock value

$ 219,000

Monthly consultant charges

$ 5,000

ArKo European Business & Services [Member] | Consulting Agreement Two [Member]

Common stock, shares issued

2,000

2,000

Commencing agreement date

May 1, 2017

Consulting agreement period

5 months

Common stock value

$ 14,400

$ 14,400

Price per share

$ 7.20

$ 7.20

ArKo European Business & Services [Member] | Consulting Agreement one [Member]

Common stock, shares issued

2,000

Commencing agreement date

May 1, 2017

Commencing terminating date

Jan. 1, 2018

Consulting agreement period

8 months

Common stock value

$ 14,400

ArKo European Business & Services [Member] | Consulting Agreement [Member]

Restricted shares of common stock

500

Consulting agreement period

4 months

Decahedron Ltd [Member] | Stock Purchase Agreement [Member]

Common stock shares reserved

170,000

Amplerissimo Ltd [Member] | Equity issued in merger [Member] | Dimitrios Goulielmos [Member]

Common stock, shares issued

10,000,000

Investor [Member] | Subscription Arrangement [Member]

Stock options granted

4,580

4,670

Price per share

$ 7

$ 5

$ 7

$ 7

Common stock value

$ 32,060

$ 21,500

$ 5,530

$ 32,690

Common Stock Shares Subscribed

4,580

4,300

790

4,670

Stock options granted fair value

$ 2,375

$ 130

$ 1,521

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes Details
Income before income taxes	$ (6,209,768)	$ (592,288)
Taxes under statutory US tax rates	(2,111,321)	(201,378)
Increase (decrease) in taxes resulting from:
Increase (decrease) in valuation allowance	156,724	193,451
Foreign tax rate differential	424,810	19,122
Tax Cuts and Jobs Act	181,881
Permanent differences	1,384,635	360
State taxes	(31,629)	(11,594)
Income tax (expense) income	$ 5,100	$ (39)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Total deferred tax asset	$ 514,338	$ 517,343
Valuation allowance	(514,338)	(517,343)
Deferred tax asset, net
United States [Member]
Net operating loss carry forward	399,115	329,848
Greece [Member]
Net operating loss carry forward	53,177	176,443
Cyprus [Member]
Net operating loss carry forward	11,274	11,052
United Kingdom [Member]
Net operating loss carry forward	$ 50,772	$ 11,052

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Federal Statutory Income Tax Rate, description	The decrease in the Company's effective tax rate in the previous years was primarily attributable to The Tax Cuts and Jobs Act (the “Act”) , which was enacted on December 22, 2017. The Act reduces the U.S. federal corporate income tax rate from 34% to 21%.
Reduction in net deferred tax assets	$ 181,881
Taxes payable	1,358,789	$ 1,080,590
Accrued other expenses	86,409
Cyprus [Member]
Net operating loss carry forward	$ 90,194
Expiration period	5 years
United Kingdom [Member]
Net operating loss carry forward	$ 406,172
Greece [Member]
Net operating loss carry forward	$ 183,369
Expiry	2,019
United States [Member]
Net operating loss carry forward	$ 1,504,390
Expiry	2,031

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Nov. 04, 2015	Dec. 19, 2017	Nov. 21, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	May 12, 2017	Jul. 22, 2009
Shares issued				12,825,393	12,587,053
Debt outstanding amount				$ 3,110,714
Repayment of related party debt				978,730	$ 15,300
Revenue				30,013,378	6,755,436
Accounts receivable balance				1,255,596	661,850
Purchase of treasury stock from officer				(94,495)
Related party accrual for repurchase of shares of common stock				61,422
Reversal of proceeds due from noteholder due to repayment of note				24,044
Officers and directors [Member]
Shares issued								2,000,000
Dimitrios Goulielmos [Member]
Aggregate forgiveness of related party notes	$ 142,860
Debt instrument decrease accrued interest forgiveness	806
Due to related party	$ 200,000		$ 401,115
Debt outstanding amount				83,553
Repayment of related party debt				84,755	63,312
Interest rate			2.00%
Maturity date			May 11, 2015
Accrued interest				0
Ourania Matsouki [Member]
Due to related party				66,121	47,479
Repayment of related party debt				120,214
Mr. Siokas [Member]
Prepaid balance				15,454	0
Return of prepayment amount				17,607
Total compensation amount				250,000
Mr. Siokas [Member]
Due to related party						$ 10,906
Repayment of related party debt						$ 10,552
Mr. Siokas [Member] | On October 1, 2016 [Member]
Due to related party				5,276
Debt outstanding amount				7,213
Short term debt, borrowing capacity				$ 1,202
Maturity date				Oct. 1, 2017
Mr. Siokas [Member] | Loan payable [Member]
Due to related party				$ 749,717	95,496
Debt outstanding amount				858,516
MediHelm S.A. [Member]
Prepaid balance				1,952,349
Accounts payable balance				385,485
Revenue					149,447
Accounts receivable balance				171,390
SkyPharm [Member]
Short term debt, borrowing capacity				6,728,606			$ 2,404,400
SkyPharm [Member] | MediHelm S.A. [Member]
Payments to acquire businesses				10,202,135	701,937
Revenue				1,429,784
DOC Pharma S.A. [Member]
Prepaid balance				933,425
Net prepaid balance				772,623
Due to related party					69
Accounts payable balance				160,801
Payments to acquire businesses				5,349,187	3,218,392
Revenue				0	$ 195,372
MediHelm S.A. [Member] | Dimitrios Goulielmos [Member]
Due to related party				233,118
Decahedron [Member] | MediHelm S.A. [Member]
Payments to acquire businesses				784,272
Tranche 1 [Member]
Purchase of treasury stock from officer				38,470
Reversal of proceeds due from noteholder due to repayment of note				24,044
Tranche [Member]
Purchase of treasury stock from officer				33,073
Related party accrual for repurchase of shares of common stock				61,422
Stock Purchase Agreement [Member] | Director [Member]
Purchase of treasury stock from officer		$ (94,495)
Purchase of treasury stock, Shares		20,000
Loan agreement [Member] | DOC Pharma S.A. [Member]
Debt outstanding amount				14,426
Accrued interest				572
Loan agreement [Member] | DOC Pharma S.A. [Member] | On November 1, 2015 [Member]
Short term debt, borrowing capacity				12,662
Payment of miscellaneous bills				$ 12,662
Interest rate				2.00%
Maturity date				Oct. 31, 2016

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 15, 2017	Dec. 31, 2017	Dec. 31, 2016
Common stock, par value		$ 0.001	$ 0.001
Debt discount		$ 3,350,000
Fair Value of Warrants		368,003
Debt outstanding amount		3,110,714
Repayment of debt		239,286
Amortization of debt discount		$ 360,890
Securities Purchase Agreement [Member] | Warrants [Member]
Common stock shares issuable upon conversion of debt/convertible securities	536,000
Proceeds from issuance of warrants	$ 2,686,000
Legal fees	$ 74,000
Maturity period	5 years
Warrants exercise price	$ 7.50
Fair Value of Warrants	$ 1,545,288
Terms of Blocker Provision	Blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company's issued and outstanding Common Stock (each, a "Blocker")
Securities Purchase Agreement [Member] | Warrants [Member] | Leak-out Agreement [Member]
Convertible notes payable, principal amount	$ 3,350,000
Debt discount	$ 240,000
Terms of agreement	As a condition to the closing of the Financing, each Buyer, severally, will be required to execute a leak-out agreement (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company’s Common Stock for three (3) trading days is less than $1.50 per share, the Company may further restrict the Buyers from selling at less than $1.50 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double.
Conditional proceeds from sale of common stock under the agreement	$ 20,000
Terms of commission to placement agent	Placement agent, received a cash commission for the transaction equal to eight (8%) percent of the total gross proceeds of the offering, or $240,000 and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors), or 53,600 shares; and, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months.
Securities Purchase Agreement [Member] | Warrants [Member] | Registration Rights Agreement [Member]
Terms of agreement	The Company is required to file, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the "Registration Rights Agreement")
Securities Purchase Agreement [Member] | Senior Convertible Notes [Member]
Common stock shares issuable upon conversion of debt/convertible securities	670,000
Common stock, par value	$ 0.001
Convertible debt, description	The Company shall pre-deliver up to 6,700,000 shares of Common Stock to the Buyers in connection therewith (the 'Pre-Delivery Shares'). Eighty-five (85%) percent of any cash proceeds received by the Buyers from the sale of Pre-Delivery Shares shall be applied against the particular installment amount due on such Installment Date under the Note. No interest will accrue under the Notes unless and until an Event of Default (as defined) has occurred and is not cured
Event of default conversion price, description	Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the "VWAP")
Debt discount	$ 1,140,711
Customary events of default, description	The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent
Debt original issue discount	$ 350,000
Purchase price charged to financing costs	240,000
Securities Purchase Agreement [Member] | Senior Convertible Note 1 [Member] | Institutional investors [Member]
Convertible notes payable, principal amount	3,000,000
Securities Purchase Agreement [Member] | Senior Convertible Note 2 [Member] | Institutional investors [Member]
Convertible notes payable, principal amount	$ 3,350,000

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)

May 12, 2017

May 05, 2017

Apr. 10, 2017

Mar. 16, 2017

Aug. 04, 2016

Mar. 04, 2016

Feb. 05, 2016

Jan. 06, 2016

Nov. 05, 2015

Mar. 04, 2015

Mar. 23, 2017

Mar. 20, 2017

Dec. 31, 2016

Oct. 18, 2016

May 24, 2016

Apr. 22, 2016

Apr. 19, 2016

Nov. 16, 2015

Dec. 31, 2017

Dec. 31, 2016

Sep. 30, 2017

Jul. 31, 2017

Jan. 31, 2017

Nov. 30, 2016

Oct. 31, 2016

Sep. 30, 2016

Sep. 13, 2016

May 04, 2016

Dec. 31, 2015

Debt outstanding amount

$ 3,110,714

Repayment of debt

239,286

Debt discount

3,350,000

Amortization of debt discount

360,890

SkyPharm [Member]

Short term debt borrowing capacity

$ 2,404,400

6,728,606

Description for the repayment

The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables.

Term of credit facility

12 months

Credit facility origination fee, percentage

2.00%

Monthly credit fee, percentage

1.00%

SkyPharm [Member] | MediHelm S.A. [Member]

Amortization of debt discount

69,269

Monthly fees

376,082

Origination fees

125,435

Second amendment to loan facility agreement [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 2,664,960

$ 452,471

70,000

$ 452,471

$ 382,327

$ 155,516

$ 250,000

$ 100,000

$ 174,000

Interest rate

10.00%

Maturity date

Aug. 4, 2016

Debt outstanding amount

3,117,287

Accrued interest

221,657

Description for the repayment

The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018.

Common stock shares reserved

1,000,000

Debt discount

126,624

42,149

126,624

Amortization of debt discount

88,322

14,507

Amendment to loan facility agreement [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 1,533,020

Debt outstanding amount

$ 240,251

Loan Facility Agreement [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 1,292,769

Interest rate

10.00%

Description for the repayment

The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility

Loan Facility Agreement [Member] | Mr. Siokas [Member] | Synthesis facility agreement [Member]

Common stock shares reserved

1,000,000

Loan Agreement 11 [Member]

Short term debt borrowing capacity

$ 10,552

Interest rate

10.00%

Maturity date

Oct. 18, 2017

Accrued interest

655

Repayment of debt

12,022

Loan Agreement 10 [Member]

Short term debt borrowing capacity

$ 52,760

Interest rate

6.00%

Maturity date

May 24, 2017

Accrued interest

1,533

Repayment of debt

60,110

Loan Agreement 9 [Member]

Short term debt borrowing capacity

$ 40,098

Interest rate

6.00%

Maturity date

Apr. 22, 2017

Accrued interest

2,136

Repayment of debt

45,684

Loan Agreement 8 [Member]

Short term debt borrowing capacity

$ 105,520

Interest rate

6.00%

Maturity date

Apr. 19, 2017

Accrued interest

3,727

Repayment of debt

120,220

Loan Agreement 7 [Member]

Short term debt borrowing capacity

$ 52,760

$ 52,760

Interest rate

6.00%

Maturity date

Mar. 4, 2017

Accrued interest

1,413

Repayment of debt

120,220

Loan Agreement 6 [Member]

Short term debt borrowing capacity

$ 21,104

$ 158,280

Interest rate

6.00%

6.00%

Accrued interest

483

1,226

483

Repayment of debt

24,044

158,280

Loan Agreement 5 [Member] | Third party [Member]

Short term debt borrowing capacity

$ 32,718

Repayment of debt

31,656

Loan Agreement 5 [Member] | Panagiotis Drakopoulos [Member]

Short term debt borrowing capacity

$ 32,718

Repayment of debt

20,437

13,718

Loan Agreement 4 [Member] | Panagiotis Drakopoulos [Member]

Short term debt borrowing capacity

$ 43,624

Interest rate

6.00%

Maturity date

Nov. 15, 2016

Debt outstanding amount

$ 20,437

Accrued interest

$ 2,477

Loan Agreement 3 [Member]

Short term debt borrowing capacity

$ 87,248

Proceeds from debt

76,342

Interest rate

5.00%

Maturity date

Nov. 5, 2016

Debt outstanding amount

68,588

$ 68,588

Accrued interest

4,087

Repayment of debt

66,121

Repayments of accounts receivable

12,022

Loan Agreement 2 [Member]

Short term debt borrowing capacity

$ 21,812

Proceeds from debt

10,906

Interest rate

1.00%

Maturity date

Nov. 5, 2016

Debt outstanding amount

12,022

Accrued interest

138

Repayment of debt

$ 2,110

9,618

Loan Agreement 1 [Member] | Angelo Drakopoulos [Member]

Short term debt borrowing capacity

$ 9,000

Repayments of outstanding bill

$ 9,000

Interest rate

8.00%

Maturity date

May 5, 2016

Debt outstanding amount

9,000

Accrued interest

1,463

Bridge Loans [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 34,745

$ 50,000

$ 120,220

Interest rate

10.00%

10.00%

10.00%

Maturity date

Sep. 30, 2017

Apr. 16, 2017

Apr. 20, 2017

Amended maturity date

May 16, 2017

May 20, 2017

Debt outstanding amount

$ 50,000

$ 120,220

34,745

Accrued interest

$ 12,851

$ 12,851

$ 2,294

Decahedron [Member] | SkyPharm [Member]

Short term debt borrowing capacity

$ 3,306,050

Description for the repayment

The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables

Term of credit facility

12 months

Credit facility origination fee, percentage

2.00%

Monthly credit fee, percentage

1.00%

COMMITMENTS AND CONTINGENCIES41

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2017USD ($)
Commitments And Contingencies Details
2,018	$ 170,394
2,019	164,463
2,020	74,255
2,021	25,813
2,022
Thereafter
Total	$ 434,925

COMMITMENTS AND CONTINGENCIES42

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

Aug. 08, 2017

May 31, 2017

Oct. 25, 2016

Jun. 30, 2016

May 31, 2016

Dec. 31, 2015

Jan. 31, 2015

Sep. 30, 2014

Dec. 31, 2017

Dec. 31, 2016

Sep. 30, 2017

Jun. 21, 2016

Operating lease periodic payment

$ 709

Frequency of periodic payment

Monthly

Operating lease rental expense

$ 8,502

$ 4,960

Operating lease expiration date

May 31, 2017

Lease agreement description

The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.

Decahedron [Member]

Operating lease periodic payment

$ 2,470

Operating lease rental expense

$ 27,180

Operating lease expiration date

Oct. 24, 2021

Private Placement [Member]

Commitments and contingencies description

(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering

SkyPharm [Member]

Operating lease periodic payment

$ 1,250

$ 4,802

Frequency of periodic payment

Monthly

Monthly

Term of operating lease

6 years

SkyPharm [Member] | Additional space [Member]

Operating lease periodic payment

$ 2,021

$ 886

Frequency of periodic payment

Monthly

Monthly

SkyPharm [Member] | First Floor [Member]

Operating lease periodic payment

$ 886

Frequency of periodic payment

Monthly

SkyPharm [Member] | MediHelm S.A. [Member]

Operating lease rental expense

116,400

89,323

Total monthly operating lease amount

8,758

CC Pharma GmbH [Member]

Non-refundable fee

$ 454,800

Expense paid

454,800

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]

Operating lease periodic payment

$ 1,500

Common stock shares reserved

200,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Preclinical Trials [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | conclusion of Phase I testing [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase II testing [Member]

Common stock shares reserved

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase III testing [Member]

Common stock shares reserved

50,000

Amplerissimo [Member]

Operating lease periodic payment

$ 124

Frequency of periodic payment

Monthly

Operating lease rental expense

$ 1,492

$ 1,462

Operating lease renewal date

Jul. 31, 2018

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Numerator for Basic and Diluted Earnings Per Share:
Net (loss) income	$ (6,209,768)	$ (601,002)
Weighted Average Shares	12,780,813	12,564,824
Potentially Dilutive Common Shares
Adjusted Weighted Average Shares	12,780,813	12,564,824
Basic and Diluted Net (Loss) Income per Share	$ (0.49)	$ (0.05)

EARNINGS PER SHARE (Details 1)

EARNINGS PER SHARE (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Diluted net loss per share	$ 677,206	$ 80,741
Convertible Debt [Member]
Diluted net loss per share	622,142
Warrant [Member]
Diluted net loss per share	38,824
Options [Member]
Diluted net loss per share	$ 16,240	$ 80,741

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Outstanding, December 31, 2016	12,000	24,000
Granted	37,000	12,000
Forfeited
Exercised		(24,000)
Expired
Outstanding, September 30, 2017	49,000	12,000
Exercisable at September 30, 2017	49,000
Weighted Average Exercise Price
Outstanding, December 31, 2016	$ 2	$ 1
Granted	1.32	2
Forfeited
Exercised		1
Expired
Outstanding, September 30, 2017	1.49	$ 2
Exercisable at September 30, 2017	$ 1.49
Weighted Average Remaining Contractual Term
Outstanding, December 31, 2016	3 years 9 months	1 year 7 days
Granted	3 years 4 months	4 years
Outstanding, September 30, 2017	3 years 2 months 8 days	3 years 9 months
Exercisable at September 30, 2017	3 years 2 months 8 days
Aggregate Intrinsic Value
Outstanding, December 31, 2016
Granted
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	426,800
Exercisable at September 30, 2017	$ 426,800

STOCK OPTIONS AND WARRANTS (D46

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Volatility
Risk-free interest rate
Expected dividend yield
Minimum [Member]
Market value of underlying stock	$ 7.20
Volatility	76.66%
Expected term (in years)	1 year
Risk-free interest rate	1.07%
Maximum [Member]
Market value of underlying stock	$ 8.50
Volatility	169.29%
Expected term (in years)	5 years 6 months
Risk-free interest rate	1.68%

STOCK OPTIONS AND WARRANTS (D47

STOCK OPTIONS AND WARRANTS (Details 2) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Outstanding, December 31, 2016
Granted	599,640
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	599,640
Exercisable at September 30, 2017	10,040
Weighted Average Exercise Price
Outstanding, December 31, 2016
Granted	7.65
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	7.65
Exercisable at September 30, 2017	$ 30
Weighted Average Remaining Contractual Term
Granted	5 years 3 months 14 days
Outstanding, September 30, 2017	5 years 3 months 14 days
Exercisable at September 30, 2017	3 months 18 days
Aggregate Intrinsic Value
Outstanding, December 31, 2016
Granted
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	1,725,921
Exercisable at September 30, 2017

STOCK OPTIONS AND WARRANTS (D48

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	Apr. 07, 2017	Nov. 16, 2017	Dec. 31, 2017	Dec. 31, 2016	Nov. 04, 2016
Stock Option [Member] | Aegis capital corp [Member]
Amortization expense			$ 94,830
Stock Option [Member] | Former director [Member] | January 5, 2013 [Member]
Stock options granted			96,000
Stock options forfeited			72,000
Exercise period			4 years
Exercise price			$ 1
Stock options/warrants value			$ 43,151
Stock price			$ 1.80
Exercise price			$ 1
Option/warrant term			4 years
Volatility rate			448.00%
Common stock shares issuable upon exercise of warrants or rights					24,000
Stock Option [Member] | Mr. Orestes Varvitsiotes [member] | January 3, 2017 [Member]
Stock options granted			12,000
Exercise period			5 years
Exercise price			$ 2
Stock options/warrants value			$ 94,830
Stock price			$ 8.20
Exercise price			$ 2
Option/warrant term			5 years
Volatility rate			155.37%
Stock option periodic vesting			12,000
Stock Option [Member] | Employee [Member] | January 1, 2017 [Member]
Stock price			$ 8.20
Exercise price			$ 1
Stock option periodic vesting			25,000
Share based compensation as annual retainer			25,000
Stock Option [Member] | Employee [Member] | On January 1, 2017 [Member]
Exercise period			4 years
Exercise price			$ 1
Stock options/warrants value			$ 195,307
Option/warrant term			4 years
Volatility rate			136.76%
Consideration under agreement			$ 1,000
Stock Option [Member] | Employee [Member] | On October 1, 2016 [Member]
Stock price			$ 5.80
Exercise price			$ 2
Stock Option [Member] | International Finance Manager [Member]
Amortization expense			$ 195,307
Stock Option [Member] | US Finance Manager [Member]
Amortization expense			$ 48,655	$ 16,636
Stock option periodic vesting				12,000
Stock Option [Member] | US Finance Manager [Member] | On October 1, 2016 [Member]
Stock options granted			12,000
Exercise period			4 years
Exercise price			$ 2
Stock options/warrants value			$ 65,290
Option/warrant term			4 years
Volatility rate			159.00%
Frequency of periodic vesting			Monthly
Securities Purchase Agreement [Member] | Roth Capital Partners, LLC [Member]
Common stock value issuable under agreement		$ 3,350,000
Warrant [Member]
Stock options forfeited
Exercise price			$ 7.65
Warrant [Member] | Private Placement [Member]
Exercise price	$ 30
Option/warrant term	1 year
Warrants issued ratio description	1:1 ratio for shares
Common stock shares issuable upon exercise of warrants or rights	10,040
Warrant [Member] | Private Placement [Member] | Minimum [Member]
Stock price	$ 7.60
Volatility rate	76.66%
Risk-free interest rate	1.07%
Warrant [Member] | Private Placement [Member] | Maximum [Member]
Stock price	$ 8.50
Volatility rate	90.86%
Risk-free interest rate	1.11%
Warrant [Member] | Securities Purchase Agreement [Member]
Stock options/warrants value		$ 1,545,288
Stock price		$ 7.20
Exercise price		$ 7.50
Option/warrant term		5 years
Volatility rate		169.29%
Common stock shares issuable upon exercise of warrants or rights		536,000
Risk-free interest rate		1.68%
Amortization period		2 years
Warrant [Member] | Securities Purchase Agreement [Member] | Roth Capital Partners, LLC [Member]
Stock options/warrants value		$ 368,003
Stock price		$ 7.20
Exercise price		$ 5
Option/warrant term		5 years
Volatility rate		169.29%
Common stock shares issuable upon exercise of warrants or rights		53,600
Risk-free interest rate		1.68%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended				12 Months Ended
	Apr. 19, 2018CAD ($)	Apr. 18, 2018USD ($)shares	Mar. 16, 2018USD ($)	Feb. 20, 2018USD ($)Integer	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 14, 2018USD ($)
Line of credit facility, borrowed amount					$ 3,110,714
Interest Paid					$ 130,531	$ 30,396
Subsequent Event [Member] | Chief Executive Officer [Member]
Due to related party			$ 246,010				$ 371,383
Subsequent Event [Member] | Mr. Siokas [Member]
Common stock shares reserved | shares		1,000,000
Subsequent Event [Member] | Advisory Agreement [Member] | Synthesis [Member]
Description for advisory agreement		SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term, all of which have been pre-paid by SkyPharm for future financing services
Subsequent Event [Member] | Loan Facility Agreement [Member] | Synthesis [Member]
Line of credit facility, borrowed amount		$ 3,117,287
Line of credit facility, interest rate		10.00%
Description for the consideration receivable under agreement		The Loan Facility permits prepayment and is due upon the earlier of (i) 75 days following demand of the Lender; or (ii) December 31, 2021, as amended.
Interest Paid		$ 136,800
Percents of quarterly Libor Payments		4.00%
Percent of default interest		2.00%
Line of credit facility, interest rate restated description		Until January 1, 2018, advances under the Loan Facility accrued interest at ten percent (10%) per annum from the applicable date of each drawdown and require quarterly interest payments. The interest rate was restated as of January 1, 2018 to four (4%) percent plus quarterly Libor Payments, plus two (2%) percent default interest on unpaid amounts in addition to the interest rate
Subsequent Event [Member] | Distribution and Equity Agreement [Member] | Marathon [Member]
Description for the term of agreement	The Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of this Agreement
Description for the consideration receivable under agreement	Following a thirty (30) day due diligence period, and subject to satisfactory due diligence of the Company, Marathon shall: (a) grant the Company a 33 1/3% equity interest in Marathon as partial consideration for the Company’s distribution services; and (b) make a cash payment of CAD $2,000,000 to the Company, subject to repayment by the Company in Common Shares of the Company if it fails to meet certain performance milestones
Amount receivable upon satisfactory due diligence	$ 2,000,000
Description for the additional consideration receivable under agreement	The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon Board of Directors
Subsequent Event [Member] | Distribution and Equity Agreement [Member] | Marathon [Member] | Target 2 [Member]
Additional consideration receivable upon meeting of target	$ 2,750,000
Gross sales target for consideration receivable	13,000,000
Subsequent Event [Member] | Distribution and Equity Agreement [Member] | Marathon [Member] | Target 1 [Member]
Additional consideration receivable upon meeting of target	2,750,000
Gross sales target for consideration receivable	$ 6,500,000
Subsequent Event [Member] | Third Party Loan Agreement [Member]
Line of credit facility, borrowed amount			$ 1,845,072
Line of credit facility, interest rate			4.70%
Line of credit facility, maturity date			Mar. 16, 2019
Subsequent Event [Member] | Amendment and Exchange of Agreements [Member] | New senior convertible note [Member]
Number of agreements | Integer				2
Maturity date, description				The New Note shall not be convertible into shares of the Company’s common stock (the “Common Stock”) until April 20, 2018
Description for the payment of installments				All future cash installment payments under such New Note will be made at a redemption price equal to 112% of the applicable installment amount
Description for the obligation to deliver predelivery shares				The Company’s existing obligation to initially deliver predelivery shares of its common stock to the holder of such New Note is deferred until April 20, 2018
Description for the redemption of the note				At any time on or before June 20, 2018, the Company has the right, at its option, to redeem all, or any part, of the amounts then outstanding under such New Note in cash at redemption price equal to 125% of such amounts then outstanding under such New Note
Senior debt				$ 3,350,000
Subsequent Event [Member] | Amendment and Exchange of Agreements 1 [Member] | New senior convertible note [Member]
Senior debt				2,791,668
Subsequent Event [Member] | Amendment and Exchange of Agreements 2 [Member] | New senior convertible note [Member]
Senior debt				$ 558,332